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CHAPTER 1
Introduction

1.1. The Obesity Pandemic
Obesity rate in the US has doubled in the last two decades with more than one
third of adults and almost 17% of children and adolescents being obese [1, 2]. There
has been a synchronized increase in obesity rates in almost all countries, likely due to
the increase in affordable processed food worldwide which in turn has created a global
overconsumption of energy [3]. While public health initiatives to manage the
prerequisites of obesity are crucial, treating its drawbacks is currently a major global
concern. This pandemic has shown a detrimental impact on health-related quality of life
of affected individuals due to obesity-related comorbidity, specifically cardiovascular
disease, type-2 diabetes, obesity-related cancers, osteoarthritis, and psychological
disturbance [4]. Needless to say, the resulting economic burden has expanded
dramatically [5, 6].
1.2. Obesity, Oxidative Stress and Diabetes
Excessive body fat is directly correlated with an increased generation of systemic
reactive oxygen species coupled with a significant reduction in the body’s antioxidant
capacity [7]. The state of chronic inflammation and oxidative stress that is thus created
is believed to play a role in promoting obesity-related complications [8, 9]. In fact, these
impairments are thought to directly lead to an inhibition of insulin responses, hence
giving rise to insulin resistance and type-2 diabetes [7, 10]. Although the exact
mechanism linking oxidative stress with altered insulin signaling is not fully understood,
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there is a consensus that impaired insulin signaling is one of the outcomes of oxidative
stress, likely through multiple pathways (Fig. 1.1) [11]. Another common metabolic
attribute linked to obesity is hyperglycemia [8, 12], which in turn has been associated
with the precipitation of oxidative stress and inflammation [13, 14], thus further
promoting diabetes and its complications [15-17]. Therefore, oxidative stress appears to
partake in both the initiation and the progression of diabetes and its related
complications [11].

Fig. 1.1. The Effect of Chronic Oxidative Stress on the Insulin Signaling Pathway.
Adapted from Rains et al, Free Radic Biol Med. 2011.
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1.3. Diabetes in the 21st Century
Given the above stated facts, it is of no surprise that the prevalence of diabetes
has risen at an alarming rate (Fig. 1.2). Diabetes currently affects 25.8 million people,
that is 8.3% of the U.S. population [18], a number that is projected to double or triple by
2050 [19]. In addition, based on fasting blood glucose or glycated hemoglobin (HbA1c)
levels, an estimated 79 million American adults have prediabetes and therefore an
increased risk of developing type-2 diabetes and other chronic conditions [18].
Particularly disturbing is the significant increase in the prevalence of type-2 diabetes
among children and adolescents, making it no longer an adult-only disease [20]. The
diabetes epidemic has become a massive health burden significantly decreasing quality
of life and increasing morbidity and mortality among Americans, all at a huge economic
cost [18, 21]. The aforesaid statistics are mostly based on an expanding prevalence of
type-2 diabetes, a condition depicted by insulin resistance and ß-cell failure with an
underlying genetic propensity profoundly influenced by lifestyle and diet [22]. This form
of diabetes accounts for about 90-95% of diabetics and begins with a state of slowly
progressing hyperglycemia [23]. Patients are at an increased risk for microvascular and
macrovascular complications which in turn lead to disability and eventually death. In
terms of microvascular complications, they typically tend to develop retinopathy,
neuropathy and nephropathy especially at advanced stages of the disease [24]. In fact,
diabetes is the leading cause of blindness and non-traumatic lower limb amputations
among US adults, and accounts for a considerable percentage of end-stage renal
disease occurrences [18]. In terms of macrovascular disease, the incidence of
cardiovascular disease and stroke increases significantly with diabetes, due to high
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levels of circulating glucose in the blood [24]. In 2004, heart disease and stroke were
noted on 68%
% and 16% of diabetes
diabetes-related
related death certificates among US seniors,
respectively. The total estimated cost of diabetes in the US was around $175 billion in
2007, and medical expenditures among diabetics were estimated to be around 2.3
times higher than those of non
non-diabetics [18].

Fig. 1.2. Age-adjusted
adjusted Prevalence of Obesity and Diagnosed Diabetes Among U.S.
U.S
Adults Aged 18 Years or Older. Source: CDC’s Division of Diabetes Translation.
http://www.cdc.gov/diabetes/statistics
http://www.cdc.gov/diabetes/statistics.
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1.4. Conventional Management of Diabetes
Anti-hyperglycemic

therapy

entails

two

aspects

of

treatment:

lifestyle

modifications and pharmaceutical interventions, with the latter being the major focus in
glycemic control. Lifestyle interventions are comprised of dietary and physical activity
regimens that promote weight loss through controlling the intake and expenditure of
energy resulting in better glycemic control [25]. In terms of pharmaceutical agents, the
biguanide metformin is the most commonly used first-line drug for type 2 diabetes. It is
an insulin sensitizer that mainly reduces hepatic glucose production [25, 26]. A less
common class of insulin sensitizers, thiazolidinediones, reduce blood glucose levels by
improving insulin sensitivity in skeletal muscle and reducing hepatic glucose output [27].
Insulin secretion from pancreatic ß-cells may be stimulated by insulin secretagogues,
namely sulfonylureas and meglitinides. A newer class of insulin secretagogues, the
injectable glucagon-like peptide-1 (GLP-1) receptor agonists, were introduced recently
and are focused on the incretin physiology in stimulating pancreatic insulin release [28].
When oral agents are contraindicated or become insufficient, insulin replacement
therapy is typically required [29]. Treatment regimens vary among patients and are
often modified based on the body’s response and disease progression.
1.5. Limitations in Diabetes Management
Conventional anti-hyperglycemic agents seem to be insufficient to contain the
widespread problem of diabetes and side effects often limit treatment choices [30, 31].
The most commonly prescribed oral therapies for type-2 diabetes, metformin and
sulfonylureas, are successful in initial reduction in blood glucose and complication rates.
However, they are often unable to provide durable glycemic control, resulting in the
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need for complicated treatment regimens [25]. Additionally, hypoglycemia and weight
gain have been reported with sulfonylureas use [32]. Thiazolidinediones have become
limited by their association with serious side effects such as weight gain, fluid retention
and bone loss [32, 33]. Despite being the most effective treatment, insulin is associated
with weight gain, hypoglycemia [30] and considerable economic costs [34]. Even newer
agents carry concerns. For instance, GLP-1 receptor agonists are accompanied by
nausea and vomiting in addition to an increased risk of pancreatitis [35]. Therefore,
there is an urgent need for alternative therapeutic strategies that will provide a broader
range of choices while addressing safety and patient-tailored treatment.
1.6. Targeting Postprandial Hyperglycemia
While the traditional goal in managing diabetes is to control fasting blood glucose
and HbA1c levels, treatment of postprandial hyperglycemia has become a compelling
target to improve overall glycemic control [36-40]. Postprandial hyperglycemia develops
early in the course of type-2 diabetes when insulin secretion becomes compromised
[39]. It has been accused of the induction of glucose toxicity and ß-cell function
deterioration which can ultimately give rise to an irreversible state of diabetes [39, 41]. It
is also an independent risk factor for the development of cardiovascular disease, the
leading cause of morbidity and mortality among diabetics [42, 43]. Postprandial
hyperglycemia is linked to the amount of consumed starch and its rate of digestion,
being the chief source of blood glucose [36]. Reducing the amount and rate of
carbohydrate digestion and absorption can be an effective approach for postprandial
hyperglycemia treatment [44-46]. This can be achieved by inhibiting starch hydrolyzing
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enzymes in the digestive tract [46-50], perhaps through the use of food-derived
phytochemicals [36, 50].
1.7. Control of Carbohydrate Digestion: α-Glucosidase Inhibition
Mammalian starch digestion takes place primarily in the small intestine through
the action of α-amylase, resulting in both linear maltose and branched isomaltose
oligosaccharides that are additionally hydrolyzed by α-glucosidases to yield glucose [5052]. Natural as well as synthetic compounds are known to reduce postprandial
hyperglycemia by inhibiting major carbohydrate digesting enzymes in the small
intestine, such as α-glucosidase (Fig. 1.3) [53-55]. Inhibition of α-glucosidases has been
shown to be effective in both preventing and treating type-2 diabetes through reducing
postprandial hyperglycemia [38, 52, 55]. However, commercial inhibitors that have been
used for diabetes treatment (i.e. Acarbose) were found to exhibit a non-specific
inhibition of α-amylase, resulting in excessive accumulation of undigested carbohydrate
in the colon, thus generating undesirable gastrointestinal side effects [36, 56, 57].
Research aiming at identifying novel inhibitors has increased in the last three decades.
For instance, numerous plant extracts rich in polyphenols and phenolic compounds
isolated from plants have been investigated and reported to be powerful inhibitors of
carbohydrate hydrolyzing enzymes [58-60].

8

Starch
(α-Amylase)

Oligo-saccharides
(α-Glucosidases)

Glucose
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Fig. 1.3. Simplified Schematic of Carbohydrate Digestion and Absorption in the Small
Intestine; Inhibition of α-Glucosidases
Glucosidases to Reduce Glucose Absorption.

1.8. Natural Products in Drug Discovery
Natural products, either as extracts or as pure compounds, possess an immense
potential as new drug leads due to their exceptional chemical diversity [61]. Plant
sources continue to serve as an inexhaustible source of bioactive compounds [62].
Concurrently, consumer demand for alternative treatments is persistently increasing. In
fact, the abundance of plant compounds is customary in natural food stores, and
unconventional therapy is becoming a common choice among many consumers.
Nevertheless, the purity of these substances is uncertain and available information
regarding dosage is limited [62, 63].. The public perception of gentleness of natural
medicines, the high
gh cost of currently available synthetic medicines, and adverse sideside
effects of pharmaceuticals have together created a need to further develop natural
products. The screening of natural preparations has become pivotal in the discovery of
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various drugs [64]. For instance, in a screening for natural, food-derived α-glucosidase
inhibitors, we identified a red grape pomace extract to be the most potent in inhibiting αglucosidases, among over 300 extracts and compounds tested [31]. Further
investigation yielded promising specificity and effectiveness data in vitro and in vivo,
respectively [31, 65]. However, comparison of a wider range of grape pomaces and
identification of the components responsible for the inhibitory activity have not been
performed, to our knowledge.
1.9. Grape-Derived Bioactives and Grape Pomace
Grapes, namely red wine cultivars, are known to be among the highest
antioxidant containing fruits [66, 67] and their pomaces have particularly been found to
be rich in polyphenols and other antioxidants [68-70]. Grape pomace is the solid
remains of grape following pressing for juice. It consists of the dry pulp with intact skin,
seeds and stem, thus retaining a considerable amount of functional compounds that
normally reside in these parts [71, 72]. Yet, grape pomace is considered a waste
byproduct generated in the winemaking industry [73]. As a result, a waste-management
issue arises from the accumulation of big loads of this byproduct annually [74]. The very
limited uses of grape pomace include recycling as animal feed, organic fertilizers, and
manure [31]. Meanwhile, grapes continue to be studied and recognized as a natural
source of prominent bioactive compounds with potential health promoting and disease
preventing properties [66, 68, 75]. For instance, remarkable amounts of polyphenolic
compounds are found in grapes, grape seed extracts and wine [75-78]. Due to their
ability to inhibit peroxidation chain reactions, dietary antioxidants have been associated
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with a reduced risk of type 2 diabetes [79, 80]. However, literature on the potential of
grape pomace as an alternative bioresource for diabetes management is very minimal.

11
CHAPTER 2
BACKGROUND, HYPOTHESIS AND SPECIFIC AIMS

Objective and Significance of the Study
Given the overwhelming rise in diabetes, it is imperative to explore novel
approaches to prevent and control it. The current research evaluated the anti-diabetic
potential of a selection of six red wine grape pomaces by determining their αglucosidase inhibiting and antioxidant activities. After selecting the most potent variety,
we isolated and identified the components responsible for the inhibiting activity, studied
their specificity and dose response, and determined their stability, cytotoxicity and
antioxidant capacity. This research may provide a foundation for the future development
of a food-derived α-glucosidase inhibitor from grape pomace for preventing and treating
diabetes, thus establishing a novel, safe dietary anti-diabetic strategy.
Hypothesis
We hypothesized that antioxidant rich red wine grape pomace contains
components that possess an anti-diabetes functional food potential through specifically
inhibiting intestinal α-glucosidases.
To test our hypothesis, we pursued 3 studies as highlighted next.
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STUDY 1: To Identify a Specific Grape Variety with Anti-Diabetes Functional Food
Potential through α-Glucosidase-Inhibiting and Antioxidant Capacities (Fig. 2.1).

Screening of plant-derived compounds for biological activity usually begins with
an initial screening involving crude extracts of multiple plants or varieties of a plant [81].
α-glucosidases play a significant role in carbohydrate digestion and therefore
postprandial blood glucose, a target for diabetes management [82]. The comparison of
the α-glucosidase inhibitory potential of several crude grape pomace extracts allows the
identification of the grape variety that is potentially rich in the inhibiting compounds.

Therefore, six red wine grape varieties were selected for screening:
Chambourcin (hybrid), Merlot (Vitis vinifera), Norton (Vitis aestivalis), Petit Verdot (Vitis
vinifera), Syrah (Vitis vinifera) and Tinta Cão (Vitis vinifera), and α-glucosidase inhibition
assay was utilized to compare their inhibiting potential.

Additionally, numerous health protective functions have been attributed to
antioxidants over the last few decades [75, 83, 84], suggesting that a bioactivity
exhibited by a grape extract may be related to its antioxidant content. A review of
literature on plant-derived α-glucosidase enzyme inhibitors indicates that known
antioxidant compounds such as polyphenols, flavonoids and others have exhibited
inhibitory activity in vitro [82, 85]. This brought about the need to investigate and
compare the antioxidant makeup of our 6 grape varieties. Total Phenolic Content (TPC)
assay is a popular method for quantifying antioxidants in a sample, as gallic acid
equivalents [86]. Antioxidant capacity is usually further assessed by evaluating the
sample’s ability to scavenge free radicals. Two assays commonly serve this purpose.
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2,2-Diphenyl-1-picrylhydrazyl (DPPH) Radical Scavenging Assay [87] and Oxygen
Radical Absorbance Capacity (ORAC) Assay with 2,2’-azobis(2-amidino-propane)
dihydrochloride (AAPH) as the free radical generator [88]. Finally, inference on
individual antioxidants in samples can be obtained via High Performance Liquid
Chromatography (HPLC) profiling using known standards for comparison [89, 90].

Hence, the abovementioned universal antioxidant assays were employed to
quantify the antioxidant content while HPLC profile comparison allowed the detection of
major differences as well as specific antioxidant compounds.
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with Anti-Diabetes
Functional Food Potential

Fig. 2.1. Schematic of the Study Design for Study 1.
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STUDY 2: To Isolate and Identify Grape Pomace Components with α-glucosidase
Inhibiting Activity via Bioactivity-Guided Fractionation (Fig. 2.2).
A crude plant extract is a complex combination of bioactive compounds and
phytochemicals, out of which only one or a few are responsible for the functional
property of interest. Separation hence poses a challenge, usually involving various
steps and multiple fractionation techniques [91]. Liquid-liquid extraction is a helpful initial
step to break down the crude extract into parts based on their relative solubility in two
different immiscible liquids [92]. When an active fraction is identified through bioassay, a
separation plan is made based on the predicted characteristics inferred from partition,
such as polarity, solubility, etc. Column chromatography is a popular method used to
purify individual chemical compounds from complex mixtures [93].
Therefore, the active grape pomace extract (GPE) was separated into fractions
via liquid-liquid extraction and sub-fractions via column chromatography on a bioactivity
guided fractionation basis to select the most active GPE sub-fraction.
Column

chromatography

often

generates

simple

fractions

of

unknown

concentrations. A sensitive purification and quantification technique must hence follow.
High Performance Liquid Chromatography (HPLC) is a powerful analytical tool that is
usually the method of choice [94]. The determination of the chemical structure and
formula of the isolated compound is then achieved via combinatorial chemistry, utilizing
compound libraries. Integration of mass spectrometry (MS) and nuclear magnetic
resonance (NMR) spectral data is the gold standard for structure verification in
analytical chemistry [95].
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Compounds within the active sub-fraction were then separated and purified using
column chromatography and HPLC and active compounds were selected by bioassay.
NMR and MS were employed to characterize the active compounds.
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Grape Pomace Extract with Anti-Diabetes
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Fig. 2.2. Schematic of the Study Design for Study 2.
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Study 3: To Determine the Applicability of the Isolated Grape Pomace Component
as a Natural Inhibitor of α-Glucosidases (Fig. 2.3).

The process of drug development requires specific measures of mode of action
and effectiveness prior to the procession to toxicological, pre-clinical and clinical testing.
Mammalian intestinal α-glucosidase enzyme complex is comprised of three enzymes:
sucrase, maltase and isomaltase, responsible for the digestion of sucrose, maltose and
isomaltose, respectively [96]. It is necessary to identify which enzyme(s) in the complex
is/are inhibited by the tested GPE components. Also, it has been reported that enzymes
falling under the glycoside hydrolase family 13 such as α-amylase (EC 3.2.1.1) and αglucosidase (EC 3.2.1.20) share a common reaction mechanism and several short
conserved sequences [97], which is why a non-specific inhibitor will likely inhibit both
enzymes. α-Amylase inhibition by our compound must be ruled out. It is also essential
to understand whether the observed bioactivity is dose-dependent. Lastly, it is important
to evaluate the antioxidant capacity of the isolated compound to draw possible relations
between α-glucosidase inhibition and antioxidant activity, and to understand the
compound’s scope of bioactivity.

For the above reasons, the active component’s enzyme inhibitory activity was
tested against α-amylase and three individual α-glucosidases to identify and verify
specificity, and antioxidant assays were employed to evaluate the antioxidant activity of
the active compound.

The problem of instability is often encountered with natural medicines. In the
course of development of an herbal drug, the determination of stability of the drug in the
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proposed active form is essential. Stability can be affected by environmental factors
such as temperature, light, air and humidity. Intrinsic factors such as particle size, pH,
and solvent properties can also have a significant impact on stability [98]. Hence, heat
treatment and pH treatment are required to determine if the product has potential use as
a commercial bioactive applicable to food products. Another necessary safety measure
is cytotoxicity studies. Given the fact that plants have been eaten and used in traditional
medicine for centuries, it is not uncommon to believe that all compounds derived from
natural sources are safe for human consumption. However, an isolated active
compound requires testing to ensure it is safe in pure form.

The effect of heat treatment on the activity of the active component was
assessed via bioassay. Similarly, bioassay was used to observe activity under various
pH levels. The inhibitory activity of the isolated compound was also assessed via
bioassay following storage under various conditions for a number of months. Lastly, the
compound was tested for cytotoxicity using a normal animal cell line.
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Fig. 2.3. Schematic of the Study Design for Study 3.

Stability

21
CHAPTER 3
α-Glucosidase Inhibiting Activity and Antioxidant Properties of Six Red Wine
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Abstract
Dietary antioxidants have been associated with a reduced risk of type 2 diabetes.
Grape pomace contains considerable amounts of polyphenols and it has been reported
that grape pomace also exhibits specific inhibitory activity against alpha- glucosidases.
This study aims to investigate the anti-diabetes potential of Chambourcin, Merlot,
Norton, Petit Verdot, Syrah and Tinta Cão red wine grape pomaces by assessing their
rat intestinal α-glucosidase inhibiting activity and antioxidant properties as well as their
relationship. Among the selected pomaces, Tinta Cão, Syrah and Merlot extracts were
the most potent inhibitors of α-glucosidase. These three varieties also appeared to have
the highest respective total phenolic content. Chambourcin, Merlot and Tinta Cão
exhibited the highest DPPH radical scavenging capacity, while Tinta Cão exceeded all
other varieties in oxygen radical (AAPH) absorbing capacity. A strong positive
correlation was observed between these results, suggesting that the α-glucosidase
inhibiting potency of grape pomace extracts may be related to their richness in
antioxidants. The phenolic compounds in the extracts were further purified and profiled
using HPLC, and major differences in the concentrations of the profiled antioxidants
were detected. However, none of these antioxidants individually was able to inhibit
intestinal α-glucosidases in bioassay. Red grape pomace, namely Tinta Cão, appears
to be a promising functional food for the future development of a food-derived αglucosidase inhibitor for preventing and treating diabetes.

Key words: Grape Pomace; Antioxidant; α-Glucosidase; Diabetes
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Introduction
The prevalence of obesity in the US has magnified in the last 20 years [2]. The
state of chronic inflammation and oxidative stress that obesity has been associated with
is believed to play a role in promoting obesity-related complications such as insulin
resistance and type-2 diabetes [8, 9]. Another common metabolic attribute linked to
obesity is hyperglycemia [8, 12], which in turn has been associated with the precipitation
of oxidative stress and inflammation [13, 14], thus further promoting diabetes and its
complications [15-17]. It is hence of no surprise that diabetes currently affects 25.8
million people in the U.S. and the number of Americans with prediabetes is on the rise.
The costs associated with diabetes and its consequences have become a significant
burden in the American society [18].
Type-2 diabetes is a chronic condition characterized by insulin resistance and ßcell failure resulting from lifestyle habits that interact with an underlying genetic
susceptibility [22]. Given the overwhelming rise in this disease, it is imperative to
explore novel approaches to prevent and control it, particularly in the light of the side
effects and limited long-term durability associate with conventional anti-hyperglycemic
agents [30]. Inhibition of α-glucosidases has been shown to be effective in both
preventing and treating type-2 diabetes through reducing postprandial hyperglycemia
[38, 55]. However, commercial inhibitors often come with gastrointestinal side effects
due to their non-specific inhibitory activity [56, 57]. This necessitates the search for
alternatives. Meanwhile, plant sources continue to serve as an inexhaustible source of
bioactive compounds [62]. In a screening for natural, food-derived α-glucosidase
inhibitors, we identified a red grape pomace extract possessing specific α-glucosidase
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inhibitory activity [31]. However, comparison of a wider range of grape pomaces and
obtaining inference on the components responsible for the inhibitory activity have not
been achieved, to our knowledge.
Grape pomace, the solid remains of grape after pressing, is commonly
considered a waste byproduct generated in the winemaking industry [73]. On the other
hand, grapes and wines are widely acknowledged as an important source of
antioxidants,

namely

polyphenolic

compounds

such

as

flavanols,

catechins,

anthocyanins, and proanthocyanidins [75-78]. Since grape pomace is chiefly comprised
of the skins and seeds, it is surmised that this biomass is a rich source of antioxidants
[68, 69, 71]. While the literature associates dietary antioxidants with a reduced risk of
type 2 diabetes [79, 80], it provides very limited information on the potential of grape
pomace as an alternative bioresource for diabetes management.
The aim of this study is to evaluate the anti-diabetic potential of a selection of six
red wine grape pomaces by determining their α-glucosidase inhibiting and antioxidant
activities as well as their relationship. This research may lay the foundation for the
future development of a safe, food-derived α-glucosidase inhibitor from grape pomace
for preventing and treating type 2 diabetes.
MATERIALS AND METHODS
Materials
The organic solvents for grape pomace extraction and HPLC analysis were
HPLC grade (Fisher Scientific, Atlanta, GA). Intestinal acetone powders from rat, 4nitrophenyl-α-D-glucopyranoside (pNPG), Folin–Ciocalteu reagent, gallic acid, 2,2-Di(4tert-octylphenyl)-1-picrylhydrazyl (DPPH) and phenolic standards including caffeic acid,
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delphinidin chloride, gallic acid, malvin chloride, malvidin chloride, quercetin hydrate and
quercetin 3-O-glucoside were purchased from Sigma-Aldrich (St. Louis, MO). 2,2′Azobis(2-amidinopropane)

dihydrochloride

(AAPH)

was

purchased

from Wako

Chemicals USA, Inc. (Richmond, VA). Acarbose and other phenolic standards including
catechin, epicatechin gallate, kaempferol, myricetin and resveratrol were obtained from
LKT Laboratories, Inc. (St. Paul, MN). Fluorescein and phenolic standards including
cyanidin chloride and p-coumaric acid were purchased from Fluka Analytical (Buchs,
Switzerland). Trolox and rutin were purchased from ACROS (Geel, Belgium).
Grape Pomace
Six red wine grape varieties: Chambourcin (hybrid), Merlot (Vitis vinifera), Norton
(Vitis aestivalis), Petit Verdot (Vitis vinifera), Syrah (Vitis vinifera) and Tinta Cão (Vitis
vinifera were kindly provided by Chrysalis Vineyards (Middleburg, VA). The pomaces
were shipped immediately after pressing. Upon receipt of the samples, they were
immediately dried in a food dehydrator at 95 oF for 28 h.
Sample Extraction
The pomaces were separated from stems and ground to a powder consistency
followed by the manual removal of visible solid impurities. Grape pomace powder was
soaked and stirred overnight at 450 rpm in aqueous acetone at a concentration of
0.1g/ml and supernatants were spun at 1,000 rpm for 5 minutes. Supernatants were
retained and filtered using a 20 µm Whatman filter paper via suction filtration with pumpgenerated vacuum. The filtered extract was then transferred to a Buchi Rotavapor
where the solvent was isolated via evaporation at 50 to 180 RPM and 40 to 60 oC, in
gradual increments, and condensation at 4-8 oC to obtain a solvent-free grape pomace
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extract in pure water. The extract was frozen at -80 oC, lyophilized and stored in powder
form at 4oC for use in screening. The prepared grape pomace extract (GPE) powders
were reconstituted with aqueous acetone and diluted with ddH2O to a concentration of
0.5 mg/ml.
α-Glucosidase Inhibition Screening
i. Preparation of rat α-Glucosidases
Intestinal acetone powders from rat were extracted with 0.05 M phosphate buffer
(PB) pH 6.8 at a concentration of 25 mg/ml. The solution was soaked and stirred
overnight at 450 RPM and supernatants were isolated and spun at 1,000 rpm for 5
minutes. Supernatants were retained and filtered via vacuum filtration using a 20 µm
Whatman filter paper. The filtered solution was frozen at -80oC, lyophilized and
reconstituted with 0.05 M PB pH 6.8 to a concentration of 25 mg/ml. Ready-to-use
aliquots of this concentration were stored at -20oC.
ii. α-Glucosidase Inhibition Assay
α-Glucosidase enzyme at 25 mg/ml was used from prepared aliquots. 4nitrophenyl-α-D-glucopyranoside (pNPG) was used as a substrate at a 4 mM
concentration. Briefly, α-glucosidase enzyme complex hydrolyzes pNPG and releases
p-nitrophenol (pNP). Reading the absorbance quantitates the release of pNP thus
representing enzymatic activity [36]. Acarbose, known to inhibit α-glucosidase enzyme
complex and used as an oral blood glucose lowering drug in diabetes [57], served as a
positive control at 50 µg/ml. Enzyme, substrate and positive control solutions were
prepared in the blank reagent (0.05 M PB pH 6.8) which is in turn used as a negative
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control. GPE samples, prepared as described above, were screened using this assay.
Ninety six-well bioassay microplates were prepared to contain 115 µl of sample or
control, 90 µl of enzyme solution and 45 µl of substrate solution per well, mixed
thoroughly. Absorbance at a wavelength of 405 nm was obtained at start of the reaction
using a Perkin Elmer HTS 7000 Bio Assay Reader and software (Perkin Elmer,
Norwalk, CT). The microplate was then incubated at 37 oC and absorbance reading was
obtained again at 30 and 90 minutes with intense shaking between cycles. The
absorbance reading, representing the concentration of pNP, was then used to compare
the activity of the tested samples: the lower the reading, the less active the enzyme, and
thus the more active the sample. Percent inhibition by all samples was calculated and
compared to controls to determine potency, using the following formula:
% Inhibition = 100 – {(Abssample/ Abscontrol) x 100}.
Antioxidant Assays
i. Total Phenolic Content (TPC) Assay
TPC was evaluated with Folin–Ciocalteu’s phenolic reagents. Samples were
diluted to 2 mg/mL with aqueous acetone. Gallic acid was used as a standard for
preparing the standard curve. All the samples and standards were run in triplicates.
Each test tube contained 25 µL of a sample or standard and 250 µL distilled water.
750 µl Folin-Ciocalteu's phenol reagent was then added to each tube and mixed using a
vortex mixer. Then, 500 µL of 200 mg/ml sodium carbonate was added to each tube
and mixed thoroughly. Samples and standards were incubated for 2 h at room
temperature in the dark. Absorbance was detected at 765 nm and the TPC of each
sample was expressed as milligrams of gallic acid equivalents (GAE) per mg GPE.
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ii. DPPH Radical Scavenging Assay
This assay measures the ability of our samples to quench DPPH radicals.
Samples were diluted to 5 mg/ml with aqueous acetone and then centrifuged at 6900
×g for 20 min to eliminate residues [99]. 100 µl of each sample was mixed with 150 µl of
DPPH radical solution in a 96-well microplate and absorbance was measured at room
temperature every 5 min for 2 h at 500 nm. All samples were prepared in triplicates.
After subtracting sample backgrounds at all time points, the percent scavenging
capacity was calculated using the following equation:
Scavenging Effect (%) = {(Absstart – Abstimepoint) /Absstart} × 100.
iii. Oxygen Radical Absorbing Capacity (ORACFL) Assay
ORACFL assay was performed as described by Zhou et al with slight
modifications. Samples were diluted with aqueous acetone to a concentration of
0.1 mg/ml. Trolox at a concentration gradient served as standard [100]. All samples and
standards were assayed in triplicates. In each well of a 96-well microplate, 200 µL of 8
µM fluorescein (in 75 mM PB pH 7.4) was mixed with 40 µL of sample or standard. The
plate was then shaken and incubated for 15 min at 37 °C and 35 µL of 0.36 M AAPH
was added to each sample, then fluorescence was measured every 5 min for 90 min at
an excitation wavelength of 485 nm and an emission wavelength of 520 nm. Results are
expressed as µmol trolox equivalent (TE)/g dried GPE weight.
High Performance Liquid Chromatography Analysis
Fifteen antioxidant compounds, typically reported in grape and wine, were used
as antioxidant standards to identify and quantify antioxidants in our GPE samples. The
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extracts were first cleaned using solid phase extraction (Oasis HLB 6 cc extraction
cartridge, Waters Corporation, Milford, MA) to remove sugar and other contaminants.
After drying with nitrogen gas, each sample/ standard was dissolved in methanol and
filtered using a 0.45 micron, 3 mm syringe filter. Reversed-phase HPLC was employed
to profile individual antioxidants in the cleaned extracts against known phenolic
standards, using a Hitachi HPLC system (Model L-2455 Diode Array Detector, Model L2200 Autosampler, Model L-2100/2130 Pump) from Hitachi High-Tech Technologies
(Tokyo, Japan). A Phenomenex Aqua 5 µm C18 250 x 4.6 mm analytical column
(Phenomenex, Torrance, CA) represents the stationary phase while methanol, 0.5%
acetic acid in 50% acetonitrile and 2% acetic acid were utilized as mobile phase
solvents A and B, respectively. Twenty µL of each sample was injected via the
autosampler at a 0-5689 psi pressure range, under room temperature. Gradient
systems were used as follows: 10–26% A, 0–8 min; 26% A, 8-15 min; 26-30% A, 15–
20 min; 30-55% A, 20–42 min; 55-87% A, 42–75 min; 87-100% A, 75-78 min; 100% A,
78-83 min; 100-10% A, 83-85 min; 10% A, 85-90 min. Flow rate was set at 1 ml/min.
Samples and standards were monitored by UV detection and profiled at a wide range of
wavelengths (200–700 nm), selecting the optimal wavelength for comparison. Profiles of
standards and samples were compared and antioxidants were detected and quantified
on the basis of their retention time and UV spectrum.
α-Glucosidase Inhibition Screening of Antioxidant Standards
The protocol described earlier was utilized. Antioxidant standards were
reconstituted in aqueous acetone to a 0.5 mg/ml concentration and screened for αglucosidase inhibiting activity.
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Statistical Analysis
Results were analyzed via IBM SPSS 22.0 for Windows (IBM Corp., Armonk,
NY) using one-way analysis of variance (ANOVA). Tukey’s HSD post-hoc analyses
were employed to compare outcomes using P < 0.05 as a cutoff point for statistical
significance. Pearson’s correlation was conducted to study the relationship between
variables. Data for each dependent variable is reported as mean + SEM.
RESULTS
Inhibition of Mammalian α-Glucosidases
Percent enzyme inhibition by GPEs is presented in Fig. 3.1. With the exception of
Petit Verdot, the selected GPEs showed potent inhibition against rat intestinal αglucosidases. At a concentration of 0.5 mg/ml, Tinta Cão exerted the strongest inhibition
of intestinal α-glucosidases, measured as 95% (P < 0.05). Chambourcin, Norton, Merlot
and Syrah also exhibited significant activity, ranging from 72% to 88% inhibition. The
inhibitory effect of these samples surpassed that of Acarbose, a commercial αglucosidase inhibitor which exerts ~50% inhibition at 50 µg/ml under the described
assay conditions. Petit Verdot, on the other hand, demonstrated a poor inhibitory activity
of 7%.
Total Phenolic Content (TPC)
As shown in Fig. 3.2, all the tested pomace samples contained noticeable
amounts of phenolic compounds at the tested concentration of 2 mg/ml, with the
exception of Petit Verdot. Merlot GPE contained the highest TPC (0.29 mg GAE/mg)
followed by Syrah GPE (0.28 mg GAE/mg), Tinta Cão GPE (0.26 mg GAE/mg),
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Chambourcin GPE (0.19 mg GAE/mg) and Norton GPE (0.14 mg GAE/mg), while Petit
Verdot GPE contained the least TPC (0.06 mg GPE/mg, P < 0.05).
DPPH Radical Scavenging
Antioxidant capacity was evaluated by DPPH radical scavenging assay. Five
milligrams of the Chambourcin, Merlot and Tinta Cão GPEs quenched 58%, 51% and
49% of DPPH radicals in the reaction at 120 min, respectively. A lesser yet remarkable
quenching of the radical was observed with similar concentrations of Syrah (36%) and
Petit Verdot (34%) GPEs. At the same conditions, Norton GPE scavenged 26% of the
DPPH radical. All values were significantly higher than the control (P < 0.05), an
identical reaction containing the sample solvent. Percent DPPH scavenging per tested
GPE is portrayed in Fig. 3.3.
Oxygen Radical Absorbance Capacity (ORACFL)
The ORACFL assay enabled the evaluation of the scavenging capability of the
selected GPEs against peroxyl radicals (AAPH). As depicted in Fig. 3.4, the six varieties
appeared to possess a notable oxygen radical scavenging activity at 0.1 mg/ml. Tinta
Cão GPE exerted the highest ORACFL value, presented as 3204. Closely, Syrah
quenched the peroxyl radical effectively at 3169 µmol TE/g, followed by Norton,
Chambourcin and Merlot GPEs which yielded the respective ORACFL values of 2918,
2878 and 2832 µmol TE/g. Petit Verdot again exhibited lower radical quenching,
estimated as 1960 µmol TE/g (P < 0.05).
Correlation
Table 3.1 summarizes the strong positive correlation that was detected when
comparing the trends observed in α-glucosidase inhibition, phenolic content, DPPH
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quenching and AAPH absorbing activity. Using Pearson’s Correlation, the association
was noted when comparing each two assays. The correlation was significant between
α-glucosidase inhibition and both TPC and ORAC (P < 0.01), as well as TPC with both
ORAC and DPPH (P < 0.01 and P < 0.05, respectively). Although DPPH assay results
did not exhibit a significantly strong correlation with either α-glucosidase inhibition or
ORAC results, there was a positive correlation.
Phenolic Acid Composition
HPLC chromatograms of standards and samples are displayed in Fig. 3.5 and
Fig. 3.6, respectively. All profiled antioxidants were detected in the 6 GPE samples, in
varying concentrations. The highest and lowest concentrations of most antioxidants
were observed in the Chambourcin and Petit Verdot varieties, respectively. The sum of
concentrations of detected antioxidant compounds was highest by far in Tinta Cão GPE
(460.6 mg/g), most attributable to the anthocyanin malvidin chloride (439.08 mg/g), and
lowest in Petit Verdot (11.13 mg/g), with consistently low concentrations of most
antioxidant compounds, except for caffeic acid (2.10 mg/g), which was most
concentrated in Petit Verdot GPE among the tested varieties. Sum of concentrations of
the profiled antioxidants ranged from 23.74 to 145.35 mg/g in the remaining varieties.
Table 3.2 summarizes the computed data.
α-Glucosidase Inhibiting Activity of Antioxidant Standards
α-Glucosidase inhibition screening of the known antioxidants detected in the six
GPE samples revealed no inhibitory activity.
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DISCUSSION
Alpha-glucosidases play a significant role in carbohydrate digestion and
absorption and therefore postprandial blood glucose, a target for diabetes management
[82]. The comparison of the α-glucosidase inhibitory potential of several crude grape
pomace extracts allows the identification of the grape variety that is potentially rich in
the inhibiting compounds. Although yeast α-glucosidase is readily available in pure form
and widely used for nutraceutical investigations [101, 102], α-glucosidase from
mammalian source is more biologically relevant. The mammalian enzyme complex was
hence extracted and purified from rat intestinal powder. The presented α-glucosidase
inhibition data is consistent with our previous findings indicating that red wine grapes
are strong inhibitors of the enzyme [31], with exception to Petit Verdot variety. Having
obtained the grape pomaces from the same vineyards and followed a consistent sample
preparation protocol, our findings suggest that Tinta Cão exceeds other tested varieties
in inhibitory activity due to varietal differences rather than differences in growth and
preparation conditions.
The richness of grapes and their pomaces in antioxidants [66-70], and the fact
that numerous health protective functions have been attributed to antioxidants over the
last few decades [75, 83, 84], together suggest that a bioactivity exhibited by a grape
extract may be related to its antioxidant content. A review of literature on plant-derived
α-glucosidase enzyme inhibitors indicates that known antioxidant compounds such as
polyphenols, flavonoids and others have exhibited inhibitory activity in vitro [82, 85].
This brought about the need to investigate and compare the antioxidant makeup of our
6 grape varieties. Hence, universal antioxidant assays were employed to quantify the
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antioxidant content while HPLC profile comparison allowed the detection of major
differences as well as specific antioxidant compounds.
According to our results, the tested grape pomace varieties are rich in phenolic
compounds, with the exception of petit verdot which had the lowest TPC value. Merlot,
Syrah and Tinta Cão pomace extracts appeared to contain the highest amounts of
phenolic compounds, with these compounds accounting for 29%, 28% and 27% of the
dried weight extract of these varieties, respectively. Although higher TPC has been
previously reported in red grape pomace extracts, like for example Norton (48%, 80%
ethanol extract) [65] and Bangalore (36%, methanol extract) [71], differences may be
attributed to source and extraction method/solvent. Interestingly, our observed trend
appears to go in parallel with our aforementioned α-glucosidase inhibition results. Our
results hence not only indicate that these three varieties are particularly rich in
antioxidants, but also hint that the antioxidant content may have contributed to the
observed enzyme inhibition potency.
DPPH radical quenching rate of 34-58% suggests that our GPE samples are
strong free radical scavengers, compared to previously tested grape extracts. For
instance, ranges of 12.5% to 66.7% have been reported with grape skin extracts [103,
104]. Amongst our tested varieties, Chambourcin, Merlot and Tinta Cão seem to exhibit
the strongest antioxidant activity in terms of quenching the DPPH radical, while Norton
demonstrated the least ability in scavenging the radical.
The tested GPEs had ORACFL values ranging between 2970 and 4878 µmol
TE/g dried pomace extract, which is remarkably higher than reported ORACFL values of
5-92 µmol TE/g fresh weight of common fruits and vegetables [65]. For instance, we
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have previously estimated the ORACFL value of Norton grape to be 22.9 µmol TE/g
fresh fruit weight [105]. It hence appears that pomace extracts exert remarkably higher
peroxyl radical scavenging activity than fresh grapes. When comparing the tested
varieties in the current study, Tinta Cão appeared to exhibit the highest ORACFL while
Petit Verdot was at the lower end of the range, in line with their α-glucosidase inhibiting
capacity and TPC levels.
When conducting correlation tests to compare the stated trends, we observed a
positive correlation between all four assays, though not particularly significant between
all pairs. α-Glucosidase inhibition data correlated strongly with both TPC and ORACFL
data suggesting that the varieties with a stronger enzyme inhibition capacity also
exhibited a stronger antioxidant capacity (peroxyl radical scavenging), likely due to their
richness in phenolic compounds. TPC appeared to be significantly correlated with both
DPPH and ORAC values. Although several studies correlating TPC and radical
scavenging results in fruits found that higher TPC does not always correspond to higher
radical absorbing ability [105, 106], many others have observed a strong positive
correlation between these parameters [20, 107, 108]. Our data is consistent with the
studies rendering high antioxidant activity to richness in phenolics [104]. Despite being
positively correlated with all assays, DPPH results were only significantly correlated with
TPC. This perhaps may be attributed to the fact that total phenolic content corresponds
to a total that contains a variety of antioxidants possessing different mechanisms of
action [109]. Furthermore, the strong α-glucosidase inhibiting activity exhibited by our
samples may be related to those polyphenols that quench the peroxyl radical, but not
necessarily the DPPH radical.
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Finally, inference on individual antioxidants in our samples was obtained via
HPLC profiling, to detect major differences that may explain the observed trends. The
anthocyanins cyanidin chloride, delphinidin chloride, malvidin chloride and malvin
chloride, the flavanols catechin and epicatechin gallate, the flavonols kaempferol,
myricetin, quercetin hydrate and quercetin 3-o-glucoside, the flavone rutin, the
hydroxycinnamates caffeic acid and p-coumaric acid, the stilbenoid resveratrol and the
non-flavonoid phenolic compound gallic acid, have been abundantly reported in grapes,
particularly red grapes and their extracts and wines [83, 110-112]. They were hence
selected as standards for antioxidant profiling in the GPE samples. As expected, the
profiled antioxidant compounds were all detected in the tested samples. Also, the total
concentration of detected antioxidants was highest with Tinta Cão and lowest with Petit
Verdot, in line with the aforementioned assay results indicating that the former
possesses strong antioxidant ability while the latter exhibits the weakest antioxidant
capacity among the tested varieties. Of interest was the search for antioxidant
compounds that are particularly deficient in the poor α-glucosidase inhibiting variety,
Petit Verdot, and antioxidant compounds that are particularly highly concentrated in the
most potent α-glucosidase inhibiting variety, Tinta Cão. Catechin, p-coumaric acid,
epicatechin gallate, quercetin 3-o-glucoside, malvidin chloride and resveratrol were
particularly very low in Petit Verdot GPE. All tested anthocyanins were especially
concentrated in Chambourcin and Tinta Cao varieties. The concentration of malvidin
chloride in Tinta Cão was 3.27 times higher than the next most concentrated variety.
This prompted the evaluation of the α-glucosidase inhibiting capacity of these
compounds, to identify the compound(s) that may be responsible for the observed
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differences between the GPE varieties. For this reason, all 15 antioxidant standards
were screened for α-glucosidase inhibiting activity. To our surprise, none of the
compounds exhibited this bioactivity, implying that the tested GPEs likely contain an
unidentified bioactive component that strongly inhibits α-glucosidases and likely exhibits
antioxidant properties. Of particular concern is the Tinta Cão variety which ranks on the
top of the list in terms of α-glucosidase inhibition along with antioxidant capacity.
Conclusion
Red wine grape extracts, namely Tinta Cão GPE, appear to be novel foodderived extracts that potently inhibit mammalian α-glucosidases. This reported activity is
new and likely specific to the grape variety and maybe related to its antioxidant content.
Although comparing antioxidant activity and content of a sample to those in the
literature can be difficult at times due to the absence of one universal method and
reporting fashion, the current results do reveal high antioxidant content/activity that
strongly correlates with α-glucosidase inhibition. These promising findings may provide
a foundation for the future development of natural α-glucosidase inhibitors from Tinta
Cão GPE to potentially use for diabetes management and prevention. Further
investigation is required to validate and optimize this property.
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FIGURES
Fig. 3.1. Percent α-Glucosidase Inhibition per GPE Sample. Enzyme activity was
determined by measuring p-nitrophenol release from pNPG at 405 nm. Acarbose (50
µg/ml) is the standard and denoted as Std. C, Chambourcin. M, Merlot. N, Norton. P,
Petit Verdot. S, Syrah. T, Tinta Cão. Bars marked with different superscripts are
significantly different (p<0.05).
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Fig. 3.2. Total Phenolic Content (TPC) per GPE Sample. TPC was determined using
Folin-Ciocalteau's reagent. Data is presented as mg gallic acid equivalents (GAE) per
mg dry GPE weight. C, Chambourcin. M, Merlot. N, Norton. P, Petit Verdot. S, Syrah. T,
Tinta Cão. Bars marked with different superscripts are significantly different (p<0.05).
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Fig. 3.3. Percent DPPH Scavenging per GPE Sample. Scavenging capacity was
measured at 500 nm using 2,2-Di(4-tert-octylphenyl)-1-picrylhydrazyl (DPPH) radical.
The reaction was conducted for 120 min. C, Chambourcin. M, Merlot. N, Norton. P, Petit
Verdot. S, Syrah. T, Tinta Cão. Control, identical reaction containing the sample solvent.
Lines marked with different letters are significantly different (p<0.05).
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Fig. 3.4. Oxygen Radical Absorbance Capacity (ORACFL) per GPE Sample. ORACFL
was determined using 2,2′-Azobis(2-amidinopropane) dihydrochloride (AAPH) as a
peroxyl radical generator. Data is presented as µmol Trolox Equivalents (TE) per g dry
GPE weight. C, Chambourcin. M, Merlot. N, Norton. P, Petit Verdot. S, Syrah. T, Tinta
Cão. Bars marked with different superscripts are significantly different (p<0.05).
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Table 3.1. Correlation between α-Glucosidase Inhibition and Antioxidant Capacity.
Correlation was measured using Pearson’s r.
NA, not applicable.
Superscripts denote statistical significance: a p<0.05; b p<0.01
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Fig. 3.5. HPLC Chromatogram of the 15 Selected Antioxidant Standards. Standards
were profiled in triplicate (one shown) to determine the anticipated retention time range
for each compound. UV spectrum is shown at 280 nm. 1, gallic acid. 2, malvin chloride.
3, catechin. 4, delphinidin chloride. 5, caffeic acid. 6, cyanidin chloride. 7, p-coumaric
acid. 8, epicatechin gallate. 9, rutin. 10, quercetin 3-o-glucoside. 11, malvidin chloride.
12, myricetin. 13, resveratrol. 14, quercetin hydrate. 15, kaempferol.
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Fig. 3.6. HPLC Chromatograms of the Six Selected GPE Samples. Antioxidant rich
concentrates isolated by solid phase extraction were profiled. Each sample is a complex
mixture of compounds, including the profiled antioxidants. Peak numbers represent
detected antioxidant standards. Spectra are displayed at 280 nm.
(a) Chambourcin. (b) Merlot. (c) Norton. (d) Petit Verdot. (e) Syrah. (f) Tinta Cão.
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Table 3.2. Concentrations of the Detected Antioxidants in the GPE Samples. Following
antioxidant detection based on retention time (RT), concentration was determined by
measuring and comparing peak area of each detected compound in the sample and the
standard chromatogram. Data is presented as milligrams of detected antioxidant per
gram of crude GPE, and numbers in green and red represent highest and lowest
concentration per row, respectively. C, Chambourcin. M, Merlot. N, Norton. P, Petit
Verdot. S, Syrah. T, Tinta Cão.
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RT Range
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0.12

4.31

4

Delphinidin chloride

17.2-17.8

0.85

0.52

0.41

0.76

5

Caffeic acid

18.2-19.2

0.74

2.10

1.14

0.86

6

24.3-26.2

0.30

0.45

0.17

0.25

0.45

7

Cyanidin chloride
p-Coumaric acid

1.51
1.24

0.70
0.48

3.78
4.95

27.9-29.2

0.42

0.13

0.13

0.03

0.12

0.21

8

Epicatechin gallate

32.2-33.5

1.16

0.38

0.02

0.43

9

Rutin

32.9-33.8

1.11

0.91

0.44
2.57

10

Quercetin 3-o-glucoside

34.5-35.5

2.55
4.05

0.26
0.39

11

Malvidin chloride

40.9-41.6

12

Myricetin

42.9-44.1

13

Resveratrol

46.1-47.3

14

Quercetin hydrate

15

Kaempferol
Total

0.37

1.59

1.27
0.05

37.65
0.86

17.93

15.38

4.57

134.14

0.31

0.48

0.18

0.30

0.21

0.38

1.10

0.27
0.29

0.08

52.9-54.0

0.65
1.26
0.21

0.24

0.23

1.18
0.17

0.33

62.9-64.1

0.27

0.84
0.33

66.06

25.27

23.74

11.13

145.35

460.60

0.72

3.29
439.08
0.47
0.88
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Abstract
Alpha-glucosidases play a major role in controlling starch digestion and therefore
postprandial blood glucose, a target for diabetes management. This study aims to
prepare and purify active components in Tinta Cão grape pomace extract (GPE) that
inhibit intestinal α-glucosidases. Tinta Cão GPE, previously shown to potently inhibit the
enzyme, was partitioned into water, butanol and ethyl acetate extracts which were
evaluated for rat intestinal α-glucosidase (25 mg/ml) inhibiting activity. The active extract
was fractionated via several open column chromatography techniques and the retained
fractions were tested. The most active fraction was further separated via HPLC and the
collected fractions were evaluated. The active compound was then identified using NMR
and MS analysis. At 0.5 mg/ml, the ethyl acetate fraction was the most effective inhibitor
of α-glucosidase (68.14% inhibition, compared to 16.28-53.4%). Aqueous ethanoleluted fractions of the HP-20 column outweighed the standard (Acarbose 50 µg/ml, 50%
inhibition) at 69.82% inhibition. HPLC purification yielded an active compound that was
later determined to be D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}.
Results were significant, suggesting that a potent inhibitor of intestinal α-glucosidases
can be isolated from Tinta Cão grapes for the potential development of a novel antihyperglycemic dietary supplement.

Key words: Grape Pomace; Tinta Cão; α-Glucosidase; Diabetes
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Introduction
The prevalence of diabetes has become overwhelming. Diabetes currently
affects 8.3% of the U.S. population [18], a number that is projected to double or triple by
2050 [19]. This epidemic has become a massive health burden significantly decreasing
quality of life and increasing morbidity and mortality among Americans, all at a huge
economic cost [21].
This alarming global rise in diabetes rates has made it necessary to explore
novel approaches to prevent and control the disease. Traditional anti-hyperglycemic
agents have shown limited long-term efficacy and often come with considerable side
effects [31]. The huge economic costs, inability to provide durable glycemic control as
well as the development of side effects ranging from hypoglycemia to impaired
gastrointestinal function have raised concerns regarding the use of common antihyperglycemic agents, namely metformin, sulfonylureas, thiazolidinediones, GLP-1
receptor agonists, and even insulin [25, 29, 30, 32-35]. Therefore, it is crucial to develop
alternative therapeutic strategies that will broaden treatment options and provide a safe
and affordable substitute to currently available therapies.
In the shift from the traditional management of blood glucose, treatment of
postprandial hyperglycemia has become an intriguing target to improve overall glycemic
control [36-40]. Postprandial hyperglycemia, one of the earliest signs of type-2 diabetes,
is thought to aggravate the disease by inducing glucose toxicity and ß-cell function
deterioration which can ultimately give rise to an irreversible state of diabetes [39, 41].
Since it is linked to the amount of consumed starch and its rate of digestion [36],
postprandial hyperglycemia can be managed by controlling carbohydrate digestion and
absorption [44-46], specifically by inhibiting digestive enzymes responsible for the
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break-down of starch [46-50]. For instance, the inhibition of α-glucosidases is effective
in both preventing and treating type-2 diabetes through reducing postprandial
hyperglycemia [52]. However, available inhibitors that have been used for diabetes
treatment (i.e. Acarbose) were found to exhibit a non-specific inhibition of α-amylase,
resulting in excessive accumulation of undigested carbohydrate in the colon, thus
generating undesirable gastrointestinal side effects [36]. Research aiming at identifying
novel inhibitors has increased in the last three decades. We have recently found several
antioxidant rich red grape pomace extracts (GPEs), namely the Tinta Cão variety, to
possess an impressive α-glucosidase inhibiting property (Chapter 3). The components
responsible for this activity are unknown, to our knowledge.
The current research aims to isolate and identify the component(s) in Tinta Cão
GPE responsible for its observed α-glucosidase inhibiting activity. The results may pave
the way for the future development of a natural α-glucosidase inhibitor from red wine
grapes, thus establishing a novel anti-diabetic strategy.
MATERIALS AND METHODS
Materials
HPLC grade organic solvents were utilized for grape pomace extraction, column
chromatography and HPLC analysis (Fisher Scientific, Atlanta, GA). Intestinal acetone
powders from rat and 4-nitrophenyl-α-D-glucopyranoside (pNPG) were purchased from
Sigma-Aldrich (St. Louis, MO). Acarbose was obtained from LKT Laboratories, Inc. (St.
Paul, MN). HP-20 Diaion Resin Styrenic Adsorbent was purchased from Sorbent
Technologies (Atlanta, GA).

60
Grape Pomace Extract Preparation
Grape pomace extraction procedure described in Chapter 3 was followed. Tinta
Cão (Vitis vinifera) grape pomace was kindly provided by Chrysalis Vineyards
(Middleburg, VA) via the Agricultural Research Station at Virginia State University
(Petersburg, VA). Briefly, Fresh pomace was dried in a food dehydrator at 95 oF for 28 h
then ground to a powder consistency. Grape pomace powder was soaked and stirred
overnight in aqueous acetone and supernatants were spun then filtered via suction
filtration. The solvent was then isolated from the extract via evaporation and
condensation. The water extract was lyophilized to then be reconstituted with aqueous
acetone.
Bioactivity-Driven Fractionation of GPE
i. Liquid-Liquid Partition
A batch-wise single stage extraction method was followed. The water-GPE
solution of aqueous acetone grape extraction was mixed with an equal volume of ethyl
acetate in a separating funnel. The solution was exposed to repetitive intervals of
vigorous shaking and rest until two distinct layers were observed. The isolated aqueous
phase was exposed to another round of batch-wise single stage extraction with butanol.
The ethyl acetate and butanol fractions were air-dried overnight and the water fraction
was dried via rota-evaporation and sublimation. Powder fractions obtained were stored
at 4 oC for future use.
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ii. Column Chromatography Separation
Open glass columns were packed with silica gel (normal phase), diaion HP-20
(reversed-phase), C18 (reversed-phase), Sephadex LH-20 (molecular sizing), Cyano
sorbent (universal phase) and Dowex resin (ion exchange). These stationary phases
were examined for their capacity for separation with acetone, methanol, ethyl acetate
and methylene chloride being used as eluents. The method yielding sub-fraction(s) with
highest enzyme inhibition potency and potential for reproducibility was selected as the
optimal fractionation method. After extensive evaluation and comparison, HP-20 open
column was selected, using HP-20 Diaion Resin Styrene-Divinylbenzene Adsorbent, a
polyaromatic adsorbent. Resin properties were as follows: 260 Å porosity, 250-850 µm
particle size, 600 m2/g surface area, 680 g/L bulk density, and 55-65% water content.
The column used was a Synthware 45/50 ST joint, 2.7 x 22 in column (VWR
International, Radnor, PA). Eluents were 100% H2O, 30% ethanol, 50% ethanol, 70%
ethanol, and 100% ethanol. Thin layer chromatography (TLC) and HPLC were then
used to determine the point in the separation process when a single pure active
compound has been isolated.
iii. High Performance Liquid Chromatography (HPLC) Purification
HPLC method previously utilized (Chapter 3) was employed with slight
modifications. The rotaevaporation-dried GPE sub-fractions were dissolved in methanol
and filtered using a 0.45 micron, 3 mm syringe filter. Reversed-phase HPLC was
employed to study purity and separate compounds, using a Hitachi HPLC system from
Hitachi High-Tech Technologies (Tokyo, Japan). A Macherey-Nagel Phenomenex 5 µm
C18 250 x 10 mm analytical column (Macherey-Nagel Inc., Bethlehem, PA) represents
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the stationary phase while methanol and H2O were utilized as mobile phase solvents A
and B, respectively. Twenty µL of a sub-fraction was injected via the autosampler at a 05689 psi pressure range, under room temperature. Gradient systems were used as
follows: 0–35% A, 0–3 min; 35% A, 3-10 min; 35-53% A, 10–13 min; 53% A, 13–16 min;
53-100% A, 16–20 min; 100% A, 20-22 min; 100-35% A, 22-25 min; 35% A, 25-28 min.
Flow rate was set at 2.5 ml/min. Samples were monitored by UV detection (220-310
nm) thus determining whether each sample is a pure compound or a complex mixture.
Complex mixtures were separated, and retained compounds/ simple fractions of the
injected sample were collected in a Foxy Jr. Fraction Collector (Teledyne Isco, Lincoln,
NE).
Chemical Structure Elucidation
NMR in combination with MS was performed in the Chemistry Department at
Wayne State University to elucidate the structure of the isolated active compound(s).
The compounds were analyzed on a Waters LCT Premier high resolution exact mass
spectrometer (Waters Corp., Milford, Massachusetts). NMR spectra (1H,

13

C, DEPT)

was generated using a Varian Mercury 400 MHz instrument (Varian, Inc., Palo Alto,
California). Through analysis of chromatograms and spectra, and comparison with data
previously reported in the literature, the chemical structure of the compound(s) was
determined.
α-Glucosidase Inhibition Screening
As previously described (Chapter 3), Intestinal acetone powders from rat were
extracted with 0.05 M phosphate buffer (PB) pH 6.8, and retained α-glucosidase
enzyme extract was reconstituted with the same buffer to a concentration of 25 mg/ml.
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Four mM 4-nitrophenyl-α-D-glucopyranoside (pNPG) was used as a substrate while 50
µg/ml Acarbose served as a positive control. Ninety six-well bioassay microplates were
prepared to contain 115 µl of GPE fraction/ sub-fraction or control, 90 µl of enzyme
solution and 45 µl of substrate solution per well. Absorbance was obtained at a 405 nm
wavelength at the start of the reaction and following a 30 min incubation at 37 oC, using
a Perkin Elmer HTS 7000 Bio Assay Reader and software (Perkin Elmer, Norwalk, CT).
Percent inhibition by tested samples was calculated using the following formula:
% Inhibition = 100 – {(Abssample/ Abscontrol) x 100}.
Statistical Analysis
Results were analyzed using one-way analysis of variance (ANOVA) and Tukey’s
HSD post-hoc analyses, comparing outcomes with P < 0.05 indicating statistical
significance. SPSS 22.0 for Windows (IBM Corp., Armonk, NY) was utilized to perform
these tests. Data for each dependent variable is reported as mean + SEM.
RESULTS
Inhibition of Mammalian α-Glucosidases
i. Activity of GPE Fractions
Two of the Tinta Cão GPE fractions significantly suppressed rat intestinal α-glucosidase
enzyme activity. Percent enzyme inhibition by GPE fraction is presented in Fig. 4.1. At a
concentration of 0.5 mg/ml, the ethyl acetate-soluble fraction of Tinta Cão GPE exerted
the strongest inhibition of intestinal α-glucosidases, measured as 68.14% (P < 0.05).
The water-soluble fraction exhibited a lesser yet remarkable inhibitory effect (53.4%),
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comparable to the effect of the standard Acarbose, a commercial α-glucosidase inhibitor
which exerts ~50% inhibition at 50 µg/ml under the described assay conditions.
ii. Activity of GPE Sub-Fractions
Following TLC-assisted elimination of redundant EA-GPE-derived sub-fractions,
it was determined that 5 sub-fractions (at 0.5 mg/ml) outweighed the standard in
enzyme inhibition. Fraction 2 of the HP-20 open column, eluted with 30% (v/v) ethanol,
exhibited 69.82% inhibition. It was selected for further fractionation since it was
significantly more active than all tested sub-fractions and the standard (P < 0.05), and it
appeared more reproducible than the others. Furthermore, HPLC analysis revealed that
this fraction is a mixture of a small number of compounds. Activity of sub-fractions is
summarized in Fig. 4.2.
iii. Activity of GPE-Derived Pure Compounds
HP-20 fraction 2 underwent HPLC purification yielding four HPLC fractions, as
shown in Fig. 4.3. Fractions 1, 2 and 3 consisted of single compounds, whereas fraction
4 was likely not a single compound. As portrayed in Fig. 4.4, upon α-glucosidase
inhibition screening, it appeared that compounds 1 and 2 possessed the inhibitory
activity under question, with 67.73% and 75.34% inhibition, respectively. On the other
hand, no remarkable activity was observed with fractions 3 and 4. Compounds 1 and 2
were hence selected for chemical characterization.
Identification of Active Compound
Upon NMR and MS analysis, it appeared that compounds 1 and 2 are identical.
They are conformational isomers of the same compound. The NMR and MS spectra of
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the isolated active compound, shown to exhibit a strong α-glucosidase inhibition, are
presented in Fig. 4.5. The structure, which was later elucidated, is presented in Fig. 4.6.
The

compound

was

determined

to

be:

D-Glucopyranose

6-{(2E)-3-(4-

Hydroxyphenyl)prop-2-enoate}, a phenyl glycoside. A review of the literature determines
that it was reported once by Huang et al., isolated from Picrorhiza scrophulariiflora
[113]. The compound is a yellowish powder, soluble in water, phosphate buffers and
universal organic solvents. One Kg of dry Tinta Cão grape pomace yielded 7.65 mg of
the active compound, following the above-mentioned fractionation and purification
methods.
DISCUSSION
Research investigating the biological activity of plant-derived components
commonly requires the isolation and characterization of bioactive compounds prior to
proceeding to further evaluation [91, 114, 115]. A crude plant extract is a complex
combination of bioactive compounds and phytochemicals, out of which only one or a
few are responsible for the functional property of interest. Separation hence poses a
challenge, usually involving various steps and multiple fractionation techniques [91].
Liquid-liquid extraction is a helpful initial step to break down the crude extract into parts
with

different

properties,

based

on

components’

relative solubility in

two

different immiscible liquids [92]. The active components of interest in our search for αglucosidase inhibiting components in Tinta Cão GPE were mostly concentrated in the
ethyl acetate-soluble fraction. Column chromatography, a popular fractionation method
[93], was then employed to further fractionate the ethyl acetate-soluble fraction of Tinta
Cão GPE, followed by HPLC for further purification and analysis. The latter yielded four
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simplified fractions of which three were determined to be pure compounds according to
UV spectra. However, they were not identified as known compounds. Bioassay was
again required to determine the activity of the generated samples and select the
bioactive entity, and it suggested that two of the isolated compounds are strong
inhibitors of α-glucosidase.
The determination of the chemical structure and formula of the isolated compound was
then achieved via combinatorial chemistry. Confirmation usually relies on verification of
information by comparison of liquid chromatography-mass spectrometry (LC-MS) and
nuclear magnetic resonance (NMR) data. Utilizing these techniques along with
reviewing

the

literature

indicated

that

the

active

compounds

were

actually

conformational isomers of the same compound and determined this compound to be DGlucopyranose

6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate},

a

phenyl

glycoside

previously characterized by Huang et al [113]. The review of the literature also indicates
that this compound has not been previously investigated for bioactivity, particularly αglucosidase inhibition and antioxidant capacity. A natural, food-derived compound
possessing the potential for the development of an anti-hyperglycemic supplement is a
very promising future anti-diabetic strategy.
Conclusion
Tinta Cão grape is a biomass that possesses a remarkable ability to inhibit
mammalian α-glucosidases. This property appears to be derived from at least one
compound, D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, isolated from
the pomace of this grape variety (Fig. 4.7). These findings are new and carry promising
potential for the future development of a novel food-derived natural supplement for
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diabetes management and prevention. Further assessing the safety and applicability of
this compound will aid in determining the future directions.
FIGURES
Fig. 4.1. Percent α-Glucosidase Inhibition per GPE Fraction. Enzyme activity was
determined by measuring p-nitrophenol release from pNPG at 405 nm. Acarbose (50
µg/ml) is the standard and denoted as Std. H2O, water fraction. EA, ethyl acetate
fraction. BuOH, butanol fraction. Bars marked with different superscripts are significantly
different (p<0.05).
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Fig. 4.2. Percent α-Glucosidase Inhibition per GPE Sub-Fraction. Enzyme activity was
determined by measuring p-nitrophenol release from pNPG at 405 nm. Acarbose (50
µg/ml) is the standard and denoted as Std. C18, reverse phase C18 column. HP20,
diaion resin HP-20 column. SPE, solid phase extraction. S1, silica gel column 1. S2,
silica gel column 2. Bars marked with different superscripts are significantly different
(p<0.05).
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Fig. 4.3. HPLC Chromatogram of GPE-Derived Active Sub-Fraction. S, solvent peak. 1,
fraction 1, single compound. 2, fraction 2, single compound. 3, fraction 3, single
compound. 4, fraction 4, likely not a single compound.
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Fig. 4.4. α-Glucosidase Inhibitory Activity of GPE-Derived HPLC Fractions. Enzyme
activity was determined by measuring p-nitrophenol release from pNPG at 405 nm.
Acarbose (50 µg/ml) is the standard and denoted as Std. 1, compound 1. 2, compound
2. 3, compound 3. 4, HPLC fraction 4. Bars marked with different superscripts are
significantly different (p<0.05).
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Fig. 4.5. NMR and MS Spectra of the Isolated Active Compound.
(a) H-NMR spectrum. (b) C-NMR spectrum. (c) MS spectrum.
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Fig. 4.6. Chemical Structure of the Isolated Active Compound. The compound was
determined

to

be:

D-Glucopyranose

6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}.

Conformational isomer 1: R1=H, R2=OH. Conformational isomer 2: R1=OH, R2=H.
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Fig. 4.7. Summary of the Active Compound Isolation Steps. Enzyme inhibition assay
followed each step. Tinta Cão grape pomace extract was subjected to liquid-liquid
partition yielding 3 fractions, of which the ethyl-acetate soluble fraction was determined
to be the strongest α-glucosidase inhibitor. This fraction was further fractionated via
multiple column chromatography techniques yielding numerous sub-fractions, of which
fraction 2 of the HP-20 column was the most potent sub-fraction. This sub-fraction was
purified via HPLC resulting in an active pure compound that was elucidated with NMR
and

MS

and

found

to

Hydroxyphenyl)prop-2-enoate}

be

consistent

with

D-Glucopyranose

6-{(2E)-3-(4-
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Abstract
This study was designed to evaluate the applicability of grape pomace-derived DGlucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate} as a natural inhibitor of αglucosidases. This compound was isolated from a Tinta Cão grape pomace extract
previously shown to be a potent inhibitor of the enzyme complex. In the current study,
the compound’s dose response in inhibiting α-glucosidases was evaluated and
specificity examination followed. Then, antioxidant activity of the compound was
evaluated by free radical assays. Thermal, pH and shelf-life stability of the active subfraction/compound was then tested after exposing it to a range of temperature, pH and
storage conditions. Lastly, cytotoxicity of the compound was determined through MTS
assay utilizing NIH/3T3 cells. The isolated compound inhibits α-glucosidase and not αamylase. Furthermore, it is a dose-dependent inhibition, exerted by predominantly
inhibiting the maltase and isomaltase moieties of α-glucosidase. The compound also
possesses an impressive antioxidant capacity. In terms of stability, it was shown to
withstand temperature and pH extremes but lose activity upon prolonged storage and
prolonged exposure to light. Lastly, at 25 and 50 µg/ml, the active compound was not
cytotoxic to cells (90% cell viability). It was concluded that the compound, besides being
a potent α-glucosidase inhibitor, is a strong antioxidant that is fairly stable under
different environmental conditions and likely safe for human consumption. These results
suggest that D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, isolated
from Tinta Cão grape pomace is a promising agent for the potential development of an
anti-hyperglycemic dietary supplement, following pre-clinical and clinical testing.
Key words: Grape Pomace; α-Glucosidase; Diabetes; Specificity; Stability; Safety
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Introduction
Diabetes rates are on a continuous dramatic increase worldwide, a trend that is
anticipated to continue over the next two decades [116]. While this epidemic is
uncontrollably spreading, currently available treatment options are often limited by
suboptimal efficacy and side effects [30, 31]. This brings about the need to develop new
approaches to prevent and control diabetes. Treatment of postprandial hyperglycemia,
a promising therapeutic target for improving overall glycemic control [36, 37, 39], can be
achieved by controlling carbohydrate digestion and absorption [44-46]. For instance,
reduction of postprandial hyperglycemia through α-glucosidase inhibition has been
effective in both preventing and treating type-2 diabetes [38, 52, 55]. Nonetheless,
commercial inhibitors (i.e. Acarbose) were found to exhibit a non-specific inhibition of αamylase due to similarities in the target enzymes, resulting in excessive accumulation of
undigested carbohydrate in the colon, which in turn gives rise to gastrointestinal side
effects [36, 56, 57].
We have observed a potent α-glucosidase inhibition exhibited by a Tinta Cão
grape pomace- derived compound (Chapter 4); however, the specificity of this
compound has not been determined. Another measure of specificity to be considered
with mammalian intestinal α-glucosidase enzyme complex is the enzyme moiety
responsible for the observed effect, as the complex consists of three enzymes: sucrase,
maltase and isomaltase, responsible for the digestion of sucrose, maltose and
isomaltose, respectively [96]. Once specificity is determined, the mechanism of action of
the agent of interest can be identified. Dose response information is essential in drug
development as it provides the necessary effectiveness and safety guidelines
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associated with dosing [117]. Testing the likelihood of dose dependence in vitro can
provide valuable information to be applied in preclinical and clinical studies.
Instability is a common problem in natural medicines. Stability tests to ensure
product quality, safety, and efficacy are required prior to the approval of any
pharmaceutical product [118]. Intermediate length testing should cover a minimum of six
months duration, however, it is considered unnecessary to continue testing if a
significant change in efficacy is seen in the first three months [119]. A loss of activity up
to 85% can lead to failure in therapy, and is considered a significant loss of activity
[118]. Another necessary safety measure is cytotoxicity studies. An isolated active
compound requires testing to ensure it is safe in pure form. The edibility of a plant is no
guarantee that its individual constituents are safe to consume, and vice versa. Plant
research is currently separated into ethnopharmacology (ex. medicinal herbs) and
toxicology (ex. poisonous plants), both leading to the production of drugs and lead
compounds [120].
Lastly, the phenolic nature of the isolated compound, as shown in Chapter 4, in
addition to the antioxidant and enzyme inhibition correlation observed in Chapter 3,
prompt the investigation of the antioxidant capacity of this compound. Plant-derived
phenolics are well known for their bioactive properties [121]. Particularly, these
compounds have exemplary antioxidant functions [122].
The current research aims to assess the safety and applicability of the isolated
compound by characterizing its inhibition mode and determining its stability and
cytotoxicity. It also aims to understand the observed correlation between α-glucosidase
inhibition and antioxidant capacity, noted in Chapter 3. This research may provide the
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groundwork for the future development of a specific, food-derived α-glucosidase
inhibitor from grape pomace for preventing and treating diabetes, thus establishing a
novel, safe dietary anti-diabetic strategy.
MATERIALS AND METHODS
Materials
Intestinal acetone powders from rat, 4-nitrophenyl-α-D-glucopyranoside (pNPG),
α-amylase from porcine pancreas type VI-B, 3,5-dinitrosalicylic acid (DNS), 2,2-Di(4tert-octylphenyl)-1-picrylhydrazyl (DPPH) and Dulbecco’s Modified Eagle’s Medium
(DMEM) were purchased from Sigma-Aldrich (St. Louis, MO). Autokit Glucose CII and
2,2′-Azobis(2-amidinopropane) dihydrochloride (AAPH) were acquired from Wako
Chemicals USA, Inc. (Richmond, VA). Maltose, sucrose and potato starch were
purchased from Fisher Scientific (Pittsburgh, PA). Isomaltose was purchased from TCI
America (Portland, OR). Acarbose was obtained from LKT Laboratories, Inc. (St. Paul,
MN). Mouse embryonic fibroblast (MEF) cell line, NIH/3T3 (CRL-1658) was obtained
from ATCC (Manassas, VA). CellTiter 96 AQueous One Solution Reagent was obtained
from Promega (Madison, WI). Fluorescein was purchased from Fluka Analytical (Buchs,
Switzerland), and Trolox was purchased from ACROS (Geel, Belgium).
α-Glucosidase Inhibition Screening
Enzyme extraction and inhibition screening methods previously described
(Chapters 3 and 4) were followed. Briefly, intestinal acetone powders from rat were
extracted with 0.05 M phosphate buffer (PB) pH 6.8, and retained, lyophilized αglucosidase enzyme extract was reconstituted with the same buffer to a concentration
of 25 mg/ml. Four mM 4-nitrophenyl-α-D-glucopyranoside (pNPG) was used as a
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substrate while 50 µg/ml Acarbose served as a positive control. Ninety six-well bioassay
microplates were prepared to contain 115 µl of sample, 90 µl of enzyme solution and 45
µl of substrate solution per well. Absorbance was obtained at a 405 nm wavelength at
the start of the reaction and following a 30 min incubation at 37 oC, using a Perkin Elmer
HTS 7000 Bio Assay Reader and software (Perkin Elmer, Norwalk, CT). Percent
inhibition by tested samples was calculated using the following formula:
% Inhibition = 100 – {(Abssample/ Abscontrol) x 100}.
Mechanism of Action Tests
i. Dose Response Test
To understand whether the observed rat α-glucosidase inhibitory effect is dosedependent, the previously described enzymatic assay was performed with multiple
concentrations of the sample (0.1, 0.25 and 0.5 mg/ml) and percent inhibition trend in
response to concentration change was calculated.
ii. Enzyme Specificity
ii.a. Pancreatic α-Amylase Inhibition Assay
Pancreatic α-amylase inhibition assay followed, using the protocol described by
Zhang et al [36] with modifications. Briefly, 50 µl of the active compound (0.5 mg/ml,
aqueous acetone) was incubated with 50 µl enzyme solution (0.17 mg/ml, ddH2O) for 5
min at room temperature. Following preincubation, 100 µl substrate solution (0.5%
potato starch, 20 mM PB pH 6.9) was added to the solution and the cocktail was
incubated for 3 min at 37oC. The reaction was stopped by adding 100 µl color reagent
(DNS) and incubating for 10-15 min at 85-90 oC. After heating, the assay cocktail was
allowed to cool for 10 min at room temperature. Fifty µl of the cocktail was then loaded
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into a well containing 175 µl ddH2O, in a 96-well assay plate. The assay was conducted
in triplicate and absorbance, representing maltose release, was measured at 540 nm
using a Perkin Elmer HTS 7000 Bio Assay Reader. The result was compared to that of
control, prepared with sample solvent instead of sample. Percent enzyme inhibition was
calculated using the following formula:
% Inhibition = 100 – {(Abssample/ Abscontrol) x 100}.
ii.b. Single α-Glucosidase Enzyme Inhibition Assay
The activity of the active compound against α-glucosidase was estimated utilizing
the active sub-fraction from which it was extracted, with different substrates to identify
specificity. The sub-fraction was reconstituted in aqueous acetone and diluted to 5
mg/ml. The sample was tested using the α-glucosidase enzyme inhibition assay
described earlier, coupled with a Mutarotase-GOD Glucose assay. The previously
described assay cocktail was prepared excluding pNPG. Instead, maltose (0.125 M),
sucrose (0.5 M) and isomaltose (0.125 M) served as enzyme substrates in three
separate assays. Glucose production in each assay represented enzymatic activity.
Glucose was detected via an Autokit Glucose CII following the manufacturer’s protocol.
Results of the three assays were compared thus identifying the target enzyme in the
multi-enzyme complex.
Antioxidant Evaluation of Active Compound
i. DPPH Radical Scavenging Assay
The protocol followed by Brand-Williams et al was modified [99]. The isolated
active compound was tested at 0.5, 1 and 5 mg/ml (in aqueous acetone) for its ability to
quench DPPH. 100 µl of sample was mixed with 150 µl of DPPH radical solution in a
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96-well microplate and absorbance was measured at room temperature every 5 min for
2 h at 500 nm. Variants were prepared in triplicates. After subtracting sample
backgrounds at all time points, the percent scavenging capacity was calculated using
the following equation:
Scavenging Effect (%) = {(Absstart – Abstimepoint) /Absstart} × 100.
ii. Oxygen Radical Absorbing Capacity (ORACFL) Assay
ORACFL assay described by Zhou et al [100] was performed with slight
modifications. Active compound was diluted with aqueous acetone to 40 and 200 µM.
Trolox which served as standard was prepared in concentrations of 0, 20, 40, 80, 100
and 200 µM in aqueous acetone. Sample variants and standards were assayed in
triplicates. In each well of a 96-well microplate, 200 µL of 8 µM fluorescein (in 75 mM
PB pH 7.4) was mixed with 40 µL of sample or standard. The plate was then incubated
for 15 min at 37 °C followed by the addition of 35 µL of 0.36 M AAPH to each well, then
fluorescence was measured every 5 min for 90 min at an excitation wavelength of
485 nm and an emission wavelength of 520 nm. Results are expressed as antioxidant
power in relative fluorescence units (RFU).
iii. ABTS Radical Cation Decolorization Assay
The protocol described by Re et al [123] was modified. 2,2′-azinobis(3ethylbenzothiazoline -6-sulfonic acid) (ABTS) was oxidized into a reactive cation by the
addition of potassium persulfate to a concentration of 7 mM ABTS/ 2.5 mM potassium
persulfate, and the cation solution was incubated in the dark at room temperature for 12
hours. After preincubation, the solution was diluted 70-fold. Then, 200 µl of the cation
solution was mixed in a well of a 96-well plate with 10 µl of control (sample solvent),
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standard (200 µM trolox) or sample (200 and 400 µM active compound). Absorbance,
representing radical cation neutralization by standard/sample, was measured at 405 nm
after 5 minutes of incubation at room temperature. Readings were recorded every
minute for 31 minutes. Percent neutralization at each time point was calculated using
the following formula:
% Neutralization = 100 – {(Abssample/ Abscontrol) x 100}.
Stability Tests
i. Thermal Stability
The active sub-fraction (reconstituted in water) was heated to 50ºC, 80ºC, 100ºC,
and 121ºC for 15 minutes using a Fisher Scientific Isotemp hot plate. Samples were
removed to ice for 10 minutes for immediate cooling. Following heat treatment, the level
of bioactivity of the samples at 1 mg/ml was assessed via α-glucosidase enzyme
inhibition assay as previously described. Untreated sample was included as control.
ii. pH Stability
Buffers were prepared at pH 3, 4, 5, 6, 7, 8, 9, and 10. Solutions of the active
sub-fraction were incubated in buffer for 4 hours. The level of bioactivity of the subfraction at different pH levels was assessed at 0.5 mg/ml via α-glucosidase enzyme
inhibition assay as previously described. Buffers at each pH value were included in this
assay as controls.
iii. Shelf-Life and Storage
The activity of the isolated active compound following storage in various
conditions was evaluated. The conditions chosen for this test were: -20ºC freezer, 3-4ºC

91
fridge, room temperature (dark), and room temperature (light). They were tested for a
period of 8 months, or until a significant loss of activity was exhibited.
MTS Assay for Cytotoxicity
The compound’s cytotoxicity was determined by MTS assay using mouse
embryonic fibroblast (MEF) cell line, NIH/3T3. MTS assay was conducted as described
by Ji et al with slight modifications [124]. The active compound was dissolved in
methanol to prepare a stock solution with a concentration of 1 mg/ml. Then, serial
dilutions with DMEM were performed to make working solutions of 25 µg/ml and 50
µg/ml, in 2.5% and 5% methanol, respectively. The NIH/3T3 cells (5 x 103) were seeded
in a 96-well culture plate and after overnight incubation, the medium was removed and
replaced with a fresh medium containing methanol (solvent control, 2.5% or 5%) or
active compound (25 or 50 µg/ml). After 72 h of incubation, 15 µl of CellTiter 96 AQueous
One Solution Reagent was added to each well. After 2 h incubation at 37 °C in a
humidified, 5 % CO2 atmosphere, absorbance was recorded at 485 nm on a Perkin
Elmer HTS 7000. Each variant of the experiment was performed in octuplicate.
Statistical Analysis
Results were analyzed via IBM SPSS 22.0 for Windows (IBM Corp., Armonk,
NY) using Student’s t-test and one-way analysis of variance (ANOVA). Tukey’s HSD
post-hoc analyses were employed to compare outcomes using P < 0.05 as a cutoff
point for statistical significance. Data for each dependent variable is reported as mean +
SEM.
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RESULTS
Mechanism of Action of the Isolated Compound
i. Dose Response
Fig. 5.1 denotes the dose-response relationship between the isolated active
compound and α-glucosidase enzyme inhibition. At 0.1 mg/ml, 0.25 mg/ml and 0.5
mg/ml of the active compound, 23.42%, 45.92% and 67.73% inhibition of the enzyme
complex were observed (P < 0.05, r2 = 0.95), respectively, indicating a dose-dependent
relationship. The linear curve had a slope of 130.82 and intercept of 6.4689, from which
IC50 was derived and determined to be 0.33 mg/ml.
ii. Enzyme Specificity
ii.a. Pancreatic α-Amylase Inhibition
Fig. 5.2 reveals that α-amylase, assayed utilizing an α-amylase inhibition assay,
was active in the presence of the isolated compound, in comparison to the standard (P
< 0.05). The isolated compound hence inhibits α-glucosidase but not α-amylase
enzyme, at 0.5 mg/ml.
ii.b. Single α-Glucosidase Enzyme Inhibition
Sucrase, maltase and isomaltase activity was observed separately utilizing αglucosidase enzyme extract with the substrates being sucrose, maltose, and
isomaltose, respectively. As shown in Fig. 5.3, the active sub-fraction appears to exert
its α-glucosidase-inhibiting activity by predominantly inhibiting maltase and isomaltase,
among the 3 enzymes that make up the enzyme complex. It exerted 48%, 49% and
16% inhibition of isomaltase, maltase and sucrase, respectively. The standard
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(acarbose), under the same conditions, predominantly inhibited maltase and sucrase,
and only showed little isomaltase inhibition.
Antioxidant Activity of Active Compound
i. DPPH Radical Scavenging
Antioxidant capacity of the active compound was evaluated by DPPH radical
scavenging assay. While 0.5 mg/ml of the compound exhibited nearly no quenching
activity (1.59%), 1 and 5 mg/ml of the compound scavenged 11.09% and 34.87% of the
DPPH radicals in the reaction at 120 min, respectively. Percent DPPH scavenging per
tested compound concentration is presented in Fig. 5.4.
ii. Oxygen Radical Absorbance Capacity (ORACFL)
The active compound’s antioxidant capacity was also evaluated via the ORACFL
assay which enabled the estimation of the scavenging capability of the active compound
against peroxyl radicals (AAPH). As depicted in Fig. 5.5, the compound appears to
possess a notable oxygen radical scavenging activity, namely by surpassing the
standard at equal concentrations. Trolox, a known scavenger of the peroxyl radical, was
used as the standard. At 200 µM, the ORACFL of the active compound was 1.9 fold that
of the standard. At 40 µM, the ORACFL of the active compound was 2.9 fold that of the
standard.
iii. ABTS Radical Cation Neutralization
The radical scavenging capacity of the active compound was further assessed
utilizing an ABTS radical cation. The compound surpassed the standard in cation
neutralization. At 31 minutes, 17.67%, 22.24% and 32.73% neutralization were
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observed with the standard, sample at 200 µM and sample at 400 µM, respectively.
ABTS cation neutralization by the active compound is presented in Fig. 5.6.
Stability of the Active Compound
i. Thermal Stability
Stability of the active sub-fraction at 37 ºC is previously established given that the
reaction is carried out at this temperature. In this test, the sub-fraction’s activity at room
temperature was used as a reference to assess its activity at 50-121 ºC. At 50 ºC, no
loss of activity was observed. At 80 and 100 ºC, 6.35% and 11.63 % loss of activity was
observed, respectively. The greatest loss of activity was observed at 121 ºC, where the
sub-fraction exhibited a 20.3% activity loss. Results are displayed in Fig. 5.7, indicating
that the active sub-fraction is thermally stable.
ii. pH Stability
Table 5.1 represents activity of the active sub-fraction following treatment with
buffers at a wide pH range. The greatest loss of activity (36.6%) was seen at a pH of 2,
and activity loss ranging from 6% to 21% was observed at the pH range of 3 to 6. At
basic pH levels, the activity of the sub-fraction appeared to increase by 4.7% and 10.5%
at pH levels of 8 and 9, respectively, and decrease by 3% at pH level of 10.
iii. Shelf-Life and Best Storage Conditions
At all storage conditions, no loss of activity was observed with the isolated
compound, when tested at 3 and 6 months, except when stored in the light (61% loss of
activity at 3 months). However, at 8 months, a complete loss of activity was observed.
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Cytotoxicity of the Isolated Compound
Fig. 5.8 represents the results of MTS assay characterizing cell viability in
presence of two different concentrations of the active compound. Sixty percent
confluent NIH/3T3 cells were incubated with the compound at 25 and 50 µg/ml. At 25
µg/ml, 87.06% of cell viability was maintained, whereas 90.6% viability was observed at
50 µg/ml. Cytotoxicity was assessed by comparing cell viability in solvent control and
treatment wells to that of wells containing cells and growth media only. When assessing
the effect of the compound with respect to the solvent control, 90.55% and 90.03% cell
viability are observed with 25 µg/ml and 50 µg/ml of the compound, respectively.
DISCUSSION
Mammalian starch digestion takes place primarily in the small intestine through
the action of α-amylase, resulting in both linear maltose and branched isomaltose
oligosaccharides that are additionally hydrolyzed by α-glucosidases to yield glucose [5052]. It was hence necessary to find out whether the active compound also exhibits a
non-specific α-amylase inhibition, a problem previously reported with α-glucosidase
inhibitors [36]. For instance Acarbose, the most widely acknowledged α-glucosidase
inhibitor, produces undesirable gastrointestinal side effects such as flatulence and
diarrhea due to this property [49, 56, 57]. The current finding indicating that the
compound is not active against pancreatic α-amylase will have strong implications on
the safety of the compound if it were to be recommended for human consumption in the
future, as it likely eliminates concerns of gastrointestinal side effects. Also, mammalian
intestinal α-glucosidase is actually a complex comprised of three individual enzymes:
sucrase, maltase and isomaltase [36]. One of our goals was also to determine which
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moiety in the complex is inhibited by the isolated compound, if not all 3 enzymes. While
Acarbose inhibits maltase and sucrase, [125], our results suggested that the active subfraction (hence the active compound) predominantly inhibits the maltase and isomaltase
moieties of intestinal α-glucosidase. Furthermore, the compound appears to exhibit a
dose-dependent inhibition of the enzyme complex, a known characteristic of acarbose
[126]. The half maximal inhibitory concentration (IC50) of the compound was determined
to be 0.33 mg/ml, suggesting that this compound may serve as a lead compound in the
future development of a therapeutic agent. IC50 is a measure of the effectiveness of a
compound in inhibiting biological or biochemical function. It represents the concentration
of a drug that is required for 50% inhibition in vitro. It is commonly used as a measure
of antagonist drug potency in pharmacological research [127]. Although the IC50 of our
pure compound is 6.6 times higher than that of Acarbose (50 µg/ml) under our assay
conditions, this compound is natural, food-derived and possesses the advantage of
specificity to α-glucosidases. These specificity and method of action properties lead to
the proposition that the GPE-derived active compound will effectively and specifically
reduce the amount and rate of carbohydrate digestion, without the risk of
gastrointestinal discomfort. These characteristics will surely require verification in vivo.
It is important to note that further mechanism of action testing was limited by the
inability to re-isolate the active compound. Detailed mode of action tests are often
required before a substance is recommended for human consumption. Measurements
of the rates of catalysis at different concentrations of substrate and inhibitor often
answer this question [128]. These tests were not completed due to the unavailability of
sufficient amounts of the isolated active compound. Bioactivity-guided fractionation
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commonly yields minute amounts of bioactive components [129], often sufficient for a
limited number of tests. Furthermore, when a bioactive component is isolated, it is not
uncommon for its re-isolation to fail even when an identical protocol is employed. Also,
the process of extract fractionation can lead to a reduction or loss of biological activity
by compound break-down, which may result in the re-isolation of an inactive or less
active component [61]. Due to the fact that plant material-derived bioactive compounds
often reside in multi-component blends, their separation and isolation remains a
challenge [91].
Our recent finding associating mammalian intestinal α-glucosidase inhibition with
antioxidant capacity of 6 red wine grape pomace extracts (Chapter 3) sparked an
interest in investigating the presence of this trend in the isolated active compound. In
fact, the compound appeared to possess a remarkable antioxidant activity. Although its
DPPH radical quenching capacity was not as prominent as that of the crude Tinta Cão
GPE at similar concentration and conditions (Chapter 3), the active compound still
scavenged 35% of the radical in the medium. On the other hand, ORACFL values of the
active compound were impressive. At the tested concentrations, it appeared to be at
least 1.9-fold more active than trolox, a known potent scavenger of the peroxyl radical,
at identical concentrations. When incubated with the ABTS radical cation, the
compound also showed a potent inhibition, outweighing the standard trolox at a similar
concentration. These striking findings suggest that the isolated compound is a novel
antioxidant compound that has not been previously investigated for this property, to our
knowledge. These results may partly explain the previously observed correlation
between α-glucosidase inhibition and antioxidant capacity. Furthermore, antioxidant
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activity exhibited by a compound found to potently inhibit α-glucosidase enzyme
function may have strong implications on diabetes management. Oxidative stress has
long been regarded as a leading factor in the progression of diabetes and development
of its chronic, mostly irreversible complications [130-132].
Glycosides such as anthocyanins are known to be sensitive to high temperatures
upon which they readily degrade or polymerize with other compounds in the medium
[133]. It was hence anticipated that our GPE-derived active compound may lose activity
upon boiling, given that it is a glycoside. Surprisingly, there was no significant loss of
activity upon exposure of the active sub-fraction to high temperatures, indicating that the
compound will likely withstand food processing temperatures if applied as a functional
food in the future.
Although plant-derived phenolic compounds have been reported to be more
stable in acidic than alkali media [134, 135], our findings suggest that the isolated
compound exhibits up to 37% activity loss at very low pH levels but remains active at
basic pH levels. The compound’s stability at high pH levels may have important
implications in its applications in food. Alkali treatment has become a common
procedure in food processing, utilized for multiple purposes, ranging from protein
recovery from cereals to the destruction of microorganisms [136].
Despite the current compound’s stability under room temperature, fridge and
freezer storage conditions for up to 6 months, it appears to lose activity after 8 months
of storage. Moreover, it displays a clear instability upon light exposure. These features
are not uncommon with plant-derived bioactives in general, and phenolic compounds in
specific. These compounds are sensitive to light, which facilitates degradation reactions
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[137]. Instability is often encountered with natural medicine, and while there may not be
a wide range of options to overcome this limitation, scientists continue to invest in
studying and developing a bioactive compound within the scope of its stability.
Cytotoxicity testing is fundamental in the process of drug discovery. It is essential
to conduct cytotoxicity studies to ensure that the product under investigation is not toxic
to animal cells [61, 138]. The current cytotoxicity results imply that the isolated
compound is not cytotoxic to cells at the tested concentrations. To note, due to shortage
of sample, only two- low concentrations- were selected for this test. However, given that
cell viability was almost identical when comparing the wells containing 25 µg/ml of
sample to those containing 50 µg/ml, it appears that cytotoxicity levels did not increase
upon doubling sample concentration. Hence, it may be safe to assume that the
compound is likely not cytotoxic at higher concentrations. This implies the likelihood that
the compound is safe for human consumption, but animal testing is recommended prior
to clinical testing.
Conclusion
Red wine grapes, specifically Tinta Cão, are a promising bioresource for the
development of an effective and likely safe to consume α-glucosidase inhibitor for the
management of diabetes, providing a dual benefit considering antioxidant capacity. At
least one component, D-Glucopyranose6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, has
proven to possess these properties. Pre-clinical and clinical investigations are
necessary future steps to validate these findings in vivo. Natural products continue to
serve as drug leads and given the unlimited availability of plants, it is imperative to
invest in research investigating the bioactive properties of plant components.
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FIGURES
Fig. 5.1. Percent Inhibition of α-Glucosidase by the Isolated Compound at Different
Concentrations. Enzyme activity was determined by measuring p-nitrophenol release
from pNPG at 405 nm. The isolated compound was assayed at 0.1, 0.25 and 0.5 mg/ml.
Points marked with different letters are significantly different (p<0.05).
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Fig. 5.2. Percent Inhibition of Pancreatic α-Amylase by the Isolated Compound. Enzyme
activity was determined by measuring maltose release from starch at 540 nm. Acarbose
(50 µg/ml) is the standard. Active compound was assayed at 0.5 mg/ml. Result is
compared with α-glucosidase inhibition (p-nitrophenol release from pNPG at 405 nm) at
similar sample and standard concentrations. Asterisk indicates significant difference
compared to standard (p<0.05).
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Fig. 5.3. Inhibition of Single α-Glucosidase Complex Enzymes by the Active SubFraction. Enzyme activity was determined by measuring glucose release from
oligosaccharides at 505 nm. Active sub-fraction (5 mg/ml) was incubated with maltose,
isomaltose and sucrose, to estimate the activity of maltase, isomaltase and sucrase,
respectively. Standard, acarbose, was subjected to similar testing.
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Fig. 5.4. Percent DPPH Scavenging per Active Compound Concentration. Scavenging
capacity was measured at 500 nm using 2,2-Di(4-tert-octylphenyl)-1-picrylhydrazyl
(DPPH) radical. The reaction was conducted for 120 min. Control, identical reaction
containing the sample solvent. Different letters represent significant difference (p<0.05).
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Fig. 5.5. Oxygen Radical Absorbance Capacity (ORACFL) of the Isolated Active
Compound.

ORACFL

was

determined

using

2,2′-Azobis(2-amidinopropane)

dihydrochloride (AAPH) as a peroxyl radical generator. Data is presented as antioxidant
power in relative fluorescence units (RFU). Active compound was compared to standard
(trolox) at equal concentrations. Asterisk indicates significant difference compared to
standard (p<0.05).
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Fig. 5.6. Percent ABTS Cation Neutralization by the Active Compound. Neutralization of
the 2,2′-azinobis(3-ethylbenzothiazoline -6-sulfonic acid) (ABTS) reactive cation was
measured at 405 nm. The reaction was conducted for 31 min. Control, identical reaction
containing the sample solvent. Different letters represent significant difference (p<0.05).
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Fig. 5.7. Thermal Stability of the Active Sub-Fraction. Enzyme activity was determined
by measuring p-nitrophenol release from pNPG at 405 nm. The active sub-fraction was
assayed at 1 mg/ml after heat treatment at 50, 80, 100 and 121 ºC. Percent enzyme
inhibition was assessed in comparison to untreated sample (room temperature),
denoted as RT.
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Table 5.1. pH Stability of the Active Sub-Fraction. Enzyme activity was determined by
measuring p-nitrophenol release from pNPG at 405 nm. The sub-fraction was assayed
at 0.5 mg/ml after treatment with buffers at pH 3, 4, 5, 6, 8, 9 and 10. Increase/reduction
in enzyme inhibiting activity was assessed in comparison to untreated sample (pH 7).
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pH Level

Maintained Activity (%)

2

63

3

79

4
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5
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6

92

7 (reference)
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8
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Fig. 5.8. Cytotoxicity of the Isolated Compound. NIH/3T3 cells were incubated with the
compound at 25 and 50 µg/ml for 72 h. Respective solvent controls are 2.5% and 5%
methanol, denoted as Control. CellTiter 96 AQueous One Solution Reagent was utilized
to quantify cell viability at 485 nm.
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Table 5.2. Summary of the Active Compound Applicability Assessment. The isolated
compound appears to inhibit α-glucosidase and not α-amylase. Furthermore, it is a
dose-dependent inhibition, exerted by specifically inhibiting the maltase and isomaltase
moieties of α-glucosidase. The compound also possesses an impressive antioxidant
capacity. In terms of stability, it was shown to withstand temperature extremes but lose
activity upon prolonged storage and prolonged exposure to light, and exhibit a partial
loss of activity upon exposure to very acidic media. Lastly, at 25 and 50 µg/ml, the
active compound was not cytotoxic to cells, proven by observing up to 90% cell viability.
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Parameter

Result

Dose-Dependent

Yes

Specificity

Maltase, Isomaltase

Inhibits α-Amylase

No

Antioxidant Property

Yes

Heat Stable

Yes

pH Stable

Yes

Shelf Life

< 8 months

Storage

Dark

Cytotoxic

No
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Summary and Future Directions
Study 1: The dramatic rise in obesity has led to a surge in type 2 diabetes rates,
increasing illness, disability and mortality worldwide. Research aiming for the
development of antidiabetic agents is hence on the rise. A now commonly studied target
for diabetes and prediabetes management is the control of post-prandial hyperglycemia,
as opposed to the traditional goal of targeting fasting hyperglycemia. This can be
achieved by controlling carbohydrate digestion and absorption, and one method is
inhibiting carbohydrate-digesting enzymes like α-glucosidase. We have previously
reported that a red wine grape pomace extract (GPE) had the strongest inhibitory
activity among hundreds of screened plant extracts. In the current study, a screening of
six red wine GPEs (Chambourcin, Merlot, Norton, Petit Verdot, Syrah and Tinta Cão)
indicated that the Tinta Cão variety possesses the strongest α-glucosidase inhibiting
capacity. Antioxidant quantification in these grape varieties revealed an interesting
trend: varieties with stronger α-glucosidase inhibitory capacity had a higher antioxidant
content and ability. This prompted HPLC antioxidant profiling of the pomace samples.
The 15 known antioxidants that appeared to vary in concentration among the 6 varieties
were not able to suppress α-glucosidase activity, suggesting that the profiled antioxidant
compounds are not in charge of the observed enzyme inhibition trend. Although the
components responsible for the observed functions were not identified, the current
results do reveal high antioxidant content/activity that strongly correlates with αglucosidase inhibition. These promising findings may provide a foundation for the future
use of grape pomace for the potential isolation and development of α-glucosidase
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inhibitor for diabetes management. Further investigation is required to validate and
optimize this property.
Future Directions: Having observed considerable differences in bioactivity among six
varieties of grape pomace, it would be beneficial in the future to screen a wider range of
grape varieties. The preparation of the enzyme in pure form as opposed to using an
enzyme-rich extract would also generate more reliable and reproducible results. Lastly,
antioxidant profiling would be more informative if more antioxidant standards are
included, thus covering a wider variety of antioxidants. These strategies will provide a
more confident foundation for the potential of utilizing GPEs for the development of an
α-glucosidase inhibitor. However, to progress with the current results, the components
in Tinta Cão GPE responsible for the observed activity must be identified.
Study 2: While diabetes rates continue to rise overwhelmingly, the main concern in
treating diabetes is glycemic control. This is typically achieved by widely available oral
medications as well as insulin and other injectables. While reliable in achieving shortterm glycemic control, they often come with side effects and fail at certain points in time.
Even

agents

targeting

post-prandial

hyperglycemia

(as

opposed

to

fasting

hyperglycemia), such as Acarbose, appear to exert a non-specific α-amylase inhibition
besides inhibiting α-glucosidases, generating undesirable gastrointestinal side effects. It
therefore appears that currently available antihyperglycemic medications are insufficient
to contain the problem. This brings about the need to explore novel agents. Among
many scientific investigations searching for natural α-glucosidase inhibitors in the last
decade, our investigation involving GPEs (study 1) yielded promising results prompting
further testing to identify the GPE components responsible for the observed activity. An
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extract is a complex combination of compounds and the search for a specific compound
or group of compounds typically requires a series of bioactivity guided fractionation
steps. In the current study, these steps were followed, yielding an active α-glucosidase
inhibiting GPE fraction, a sub-fraction, and an active pure compound that was
determined

to be D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}. The

isolation and identification of this compound may be a giant step forward for the future
development of a natural α-glucosidase inhibitor from Tinta Cão GPE to potentially use
for diabetes management and prevention.
Future Directions: Bioassay guided fractionation is a tedious process that must be
carefully planned. In our study, we ran into the problem of insufficient amount of isolated
compound. In the future, it is important to plan the separation with this point in mind.
Separating large amounts of extracts surely involves magnified waste and cost,
however, insures the isolation of a sufficient amount of the compound of interest. Also,
while only the most active fraction was fractionated into sub-fractions, in the future it
may be beneficial to attempt to fractionate the fraction that ranks next in activity (H2O
fraction in this study) which may have reduced the limitations related to chemical
characteristics. However, to further develop the current results, D-Glucopyranose 6{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate} must be tested for applicability as a potential
functional food.
Study 3: When an agent is determined to possess a health-promoting bioactivity, it has
to meet safety and stability measures before it is recommended for human
consumption. The problem of instability is not uncommon with natural products. This
makes it necessary to determine whether the product is stable under environmental
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conditions that will likely be faced before and throughout consumption, such as storage,
pH and temperature changes. It is also imperative to evaluate the safety of the product
for human consumption. Cytotoxicity tests usually provide reliable information on
whether the product will be expected to harm animal cells or not. In regards to αglucosidase inhibition, another safety measure to take into consideration relates to
possible side effects, given the nature of present inhibitors. It is important to rule out a
non-specific α-amylase inhibition which in turn indicates the likelihood that no
gastrointestinal side effects will be encountered. Alongside testing for enzyme
specificity, inhibition mode is necessary information for the development of the product
into a commercial bioactive agent. This study provided valuable inference on these
aspects. D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate} appears to be
fairly stable in terms of storage and environmental conditions, with minor limitations that
can be taken into consideration in future applications. Also, it is likely safe for human
consumption based on the negative cytotoxicity results and specificity to α-glucosidase,
to which it is a dose-dependent inhibitor. Interestingly, this compound also exhibits a
notable antioxidant capacity, which may partly explain the trend observed in study 1,
and may represent a novel antioxidant compound. These results are fundamental for
the future development of a natural, food-derived supplement for diabetes prevention
and treatment, with the dual benefit of α-glucosidase inhibition and antioxidant activity.
Future Directions: Although the current results provide valuable information on the
applicability

of

Tinta

Cão

GPE-derived

D-Glucopyranose

6-{(2E)-3-(4-

Hydroxyphenyl)prop-2-enoate} as a functional food component, further measures of
stability could be tested, such as photostability, compatibility with different storage
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containers, storage form, ability to withstand simulated digestion, etc. Stability can
further be understood by analyzing active compounds via NMR and MS to detect
structural changes. Also, enzyme kinetics must be employed to reveal the mechanism
of action. Moreover, cytotoxicity testing at higher concentrations may provide more
relevant data. It is also important to conduct further measures of antioxidant capacity,
namely more antioxidant assays (scavenging of additional radicals, lipid peroxidation
inhibition, etc) and preferably analyze a wide range of known antioxidants for
comparison, given the impressive antioxidant activity the isolated active compound
appears to posses. However, to apply the current results, further testing is required prior
to human consumption recommendation. First, pre-clinical testing should take place.
This is achieved through the administration of the product to relevant animal models, for
example diabetic mice/rats. Of interest, in addition to the effect on postprandial
hyperglycemia, is the product’s antioxidant effects in vivo, which should also be
evaluated via relevant assays (ferric reducing ability of plasma, lipid peroxidation,
inflammatory markers, etc). If the pre-clinical study validates the in vitro results with
minimal to no side effects, then clinical testing is recommended. In a clinical test, human
subjects with pre-diabetes will be observed for the effects of ingesting different doses of
the product. Safety and efficacy of the product will render it appropriate for
consideration for commercial development. These investigations will have very
important implications given the current prevalence of diabetes and the urgent need to
find alternative methods to control and prevent it.
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ABSTRACT
ISOLATION AND CHARACTERIZATION OF NATURAL α-GLUCOSIDASE
INHIBITORS FROM ANTIOXIDANT RICH RED WINE GRAPES (VITIS VINIFERA)
by
HODA KADOUH
May 2014
Advisor: Dr. Kequan Zhou
Major: Nutrition and Food Science
Degree: Doctor of Philosophy
Background: Diabetes is currently a global public health problem affecting
people at all ages. Dietary antioxidants have been associated with a reduced risk of
type 2 diabetes. Grape pomace contains considerable amounts of polyphenols and it
has been reported to exhibit an inhibitory activity against alpha- glucosidases. Alphaglucosidases, in turn, play a major role in controlling starch digestion and therefore
postprandial blood glucose, a target for diabetes management.
Objective: This study aims to investigate the anti-diabetes potential of a
selection of six grape pomaces and prepare and purify active components in the active
variety that specifically inhibit intestinal α-glucosidases. The study was also designed to
evaluate the applicability of the isolated active components as natural inhibitors of αglucosidases.
Methods: Chambourcin, Merlot, Norton, Petit Verdot, Syrah and Tinta Cão red
wine grape pomace extracts were assessed for their rat intestinal α-glucosidase
inhibiting activity and antioxidant properties via biochemical assays and UV detection.
Then, the grape pomace variety shown to potently inhibit the enzyme was subjected to
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bioactivity-guided fractionation and the isolated active component was identified via
analytical chemistry techniques. The characterized compound was then tested for
functional food applicability via stability, enzyme specificity and cytotoxicity testing.
Results: Tinta Cão grape pomace extract was the most potent α-glucosidase
inhibiting variety and possessed a remarkable antioxidant activity, both properties of
which appeared to be correlated.

HPLC analysis did not yield an antioxidant

responsible for the observed trend. Hence, bioactivity-guided fractionation of the extract
was pursued, yielding a pure active compound that was determined to be DGlucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, which also exhibited a
strong antioxidant activity. Further testing indicated that the compound inhibits αglucosidase and not α-amylase, and specifically inhibits the maltase and isomaltase
moieties of α-glucosidase, in a dose-dependent fashion. The compound was fairly
stable under different environmental and storage conditions, and it was also not
cytotoxic to animal cells.
Conclusion: Red grape pomace, namely Tinta Cão, is a promising bioresource
for the future development of a food-derived antidiabetic agent. At least one component,
D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, isolated from Tinta Cão
grape pomace appears to potently and specifically inhibit mammalian intestinal αglucosidases while exhibiting a notable ability to quench free radicals. It may thus
represent an alternative future strategy for diabetes management and a novel
antioxidant compound. Pre-clinical and clinical testing will validate the obtained results
in vivo.
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